<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:95.0pt;left:200.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">RESEARCH ARTICLE</span></p>
<p style="top:109.5pt;left:200.0pt;line-height:18.0pt"><span style="font-family:OpenSans,serif;font-size:18.0pt">Therapeutic targeting of STAT3 pathways in</span></p>
<p style="top:132.0pt;left:200.0pt;line-height:18.0pt"><span style="font-family:OpenSans,serif;font-size:18.0pt">pancreatic adenocarcinoma: A systematic</span></p>
<p style="top:154.5pt;left:200.0pt;line-height:18.0pt"><span style="font-family:OpenSans,serif;font-size:18.0pt">review of clinical and preclinical literature</span></p>
<p style="top:186.6pt;left:200.0pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">Sarah Peisl</span></b><b><span style="font-family:Arial,serif;font-size:7.5pt;color:#ffffff">ID</span></b><sup><b><span style="font-family:Arial,serif;font-size:6.4pt">1</span></b></sup><b><span style="font-family:Arial,serif;font-size:9.0pt">, Claudia Mellenthin</span></b><b><span style="font-family:Arial,serif;font-size:7.5pt;color:#ffffff">ID</span></b><sup><b><span style="font-family:Arial,serif;font-size:6.4pt">1</span></b></sup><b><span style="font-family:Arial,serif;font-size:9.0pt">, Lucie Vignot</span></b><sup><b><span style="font-family:Arial,serif;font-size:6.4pt">2</span></b></sup><b><span style="font-family:Arial,serif;font-size:9.0pt">, Carmen Gonelle-Gispert</span></b><b><span style="font-family:Arial,serif;font-size:7.5pt;color:#ffffff">ID</span></b><sup><b><span style="font-family:Arial,serif;font-size:6.4pt">3</span></b></sup><b><span style="font-family:Arial,serif;font-size:9.0pt">,</span></b></p>
<p style="top:197.7pt;left:200.0pt;line-height:9.0pt"><b><span style="font-family:Arial,serif;font-size:9.0pt">Leo Bu&#xa8;hler</span></b><sup><b><span style="font-family:Arial,serif;font-size:6.4pt">1</span></b></sup><b><span style="font-family:Arial,serif;font-size:9.0pt">, Bernhard Egger</span></b><sup><b><span style="font-family:Arial,serif;font-size:6.4pt">1,4</span></b></sup><b><span style="font-family:UniversATT,serif;font-size:9.0pt">*</span></b></p>
<p style="top:216.5pt;left:200.0pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">1</span></b><span style="font-family:Arial,serif;font-size:8.0pt"> Department of Surgery, HFR Fribourg, Fribourg, Switzerland,</span><b><span style="font-family:Arial,serif;font-size:8.0pt"> 2</span></b><span style="font-family:Arial,serif;font-size:8.0pt"> Department of Oncology, HFR Fribourg,</span></p>
<p style="top:226.4pt;left:200.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Fribourg, Switzerland,</span><b><span style="font-family:Arial,serif;font-size:8.0pt"> 3</span></b><span style="font-family:Arial,serif;font-size:8.0pt"> Surgical Research Unit, Faculty of Science and Medicine, University of Fribourg,</span></p>
<p style="top:236.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Fribourg, Switzerland,</span><b><span style="font-family:Arial,serif;font-size:8.0pt"> 4</span></b><span style="font-family:Arial,serif;font-size:8.0pt"> Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland</span></p>
<p style="top:256.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:Univers,serif;font-size:8.0pt">*</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> bernhard-egger@bluewin.ch</span></p>
<p style="top:291.5pt;left:200.0pt;line-height:14.5pt"><span style="font-family:OpenSans,serif;font-size:14.5pt">Abstract</span></p>
<p style="top:331.7pt;left:200.0pt;line-height:11.5pt"><b><span style="font-family:Arial,serif;font-size:11.5pt">Background/Objectives</span></b></p>
<p style="top:350.3pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">Pancreatic ductal adenocarcinoma is a highly lethal disease with increasing incidence. Due</span></p>
<p style="top:364.3pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">to high resistance, chemo/radiotherapy has limited success in pancreatic cancer and only</span></p>
<p style="top:378.3pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">marginally prolongs patient survival. Therefore, novel biomarkers and therapeutic targets</span></p>
<p style="top:392.3pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">are needed. In the present review, we performed a comprehensive summary of therapeutic</span></p>
<p style="top:406.3pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">approaches targeting the GP130/JAK/STAT3 pathway.</span></p>
<p style="top:434.6pt;left:200.0pt;line-height:11.5pt"><b><span style="font-family:Arial,serif;font-size:11.5pt">Methods</span></b></p>
<p style="top:453.2pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">We systematically reviewed the PubMed and Embase databases for preclinical and clinical</span></p>
<p style="top:467.2pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">studies, from inception to October 4, 2020, on drugs targeting the GP130/JAK/STAT3 path-</span></p>
<p style="top:481.2pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">way. Bias assessments and qualitative analyses were performed.</span></p>
<p style="top:509.4pt;left:200.0pt;line-height:11.5pt"><b><span style="font-family:Arial,serif;font-size:11.5pt">Results</span></b></p>
<p style="top:528.0pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">Twenty-five preclinical and nine clinical trials were included in the review. All preclinical stud-</span></p>
<p style="top:542.0pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">ies reported a favorable outcome in terms of pancreatic ductal adenocarcinoma progres-</span></p>
<p style="top:556.0pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">sion. Futhermore, drugs targeting the GP130/JAK/STAT3 pathway were shown to be</span></p>
<p style="top:570.0pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">efficient chemosensitizers. However, high publication bias was assumed. In the clinical set-</span></p>
<p style="top:584.0pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">ting, bazedoxifene and itacitinib improved patient outcomes.</span></p>
<p style="top:612.3pt;left:200.0pt;line-height:11.5pt"><b><span style="font-family:Arial,serif;font-size:11.5pt">Conclusion</span></b></p>
<p style="top:630.9pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">Preclinical studies strongly suggest significant efficacy of drugs targeting GP130/JAK/</span></p>
<p style="top:644.9pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">STAT3 in the treatment of pancreatic ductal adenocarcinoma and that these molecules are</span></p>
<p style="top:658.9pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">effective chemosensitizers. Though only a few trials have shown the efficacy in a clinical set-</span></p>
<p style="top:672.9pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">ting, the STAT3 pathway remains a promising drug target for future treatment of pancreatic</span></p>
<p style="top:686.9pt;left:200.0pt;line-height:9.5pt"><span style="font-family:Arial,serif;font-size:9.5pt">ductal adenocarcinoma and may help overcome chemotherapy resistance.</span></p>
<p style="top:31.8pt;left:34.7pt;line-height:20.6pt"><span style="font-family:Gotham,serif;font-size:20.6pt;color:#020404">PLOS </span><span style="font-family:Gotham,serif;font-size:20.6pt;color:#bc3392">ONE</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">1 / 17</span></p>
<p style="top:257.7pt;left:36.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#ffffff">a1111111111</span></p>
<p style="top:269.2pt;left:36.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#ffffff">a1111111111</span></p>
<p style="top:280.7pt;left:36.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#ffffff">a1111111111</span></p>
<p style="top:292.2pt;left:36.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#ffffff">a1111111111</span></p>
<p style="top:303.7pt;left:36.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#ffffff">a1111111111</span></p>
<img style="position:absolute;transform:matrix(.31827618,0,-0,.31933064,35.04725,461.4804)" src="data:image/png;base64,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">
<p style="top:363.2pt;left:47.6pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">OPEN ACCESS</span></p>
<p style="top:379.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Citation:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> Peisl S, Mellenthin C, Vignot L, Gonelle-</span></p>
<p style="top:390.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Gispert C, Bu&#xa8;hler L, Egger B (2021) Therapeutic</span></p>
<p style="top:401.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">targeting of STAT3 pathways in pancreatic</span></p>
<p style="top:412.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">adenocarcinoma: A systematic review of clinical</span></p>
<p style="top:423.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">and preclinical literature. PLoS ONE 16(6):</span></p>
<p style="top:434.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">e0252397.</span><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.</span></p>
<p style="top:445.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">pone.0252397</span></p>
<p style="top:462.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Editor:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> Gautam Sethi, National University</span></p>
<p style="top:473.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Singapore Yong Loo Lin School of Medicine,</span></p>
<p style="top:484.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">SINGAPORE</span></p>
<p style="top:501.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Received:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> March 12, 2021</span></p>
<p style="top:518.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Accepted:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> May 14, 2021</span></p>
<p style="top:535.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Published:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> June 17, 2021</span></p>
<p style="top:552.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Copyright:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> &#xa9;</span><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> 2021 Peisl et al. This is an open</span></p>
<p style="top:563.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">access article distributed under the terms of the</span></p>
<p style="top:574.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">Creative Commons Attribution License</span><span style="font-family:Arial Narrow,serif;font-size:8.0pt">, which</span></p>
<p style="top:585.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">permits unrestricted use, distribution, and</span></p>
<p style="top:596.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">reproduction in any medium, provided the original</span></p>
<p style="top:607.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">author and source are credited.</span></p>
<p style="top:624.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Data Availability Statement:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> All relevant data are</span></p>
<p style="top:635.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">within the paper and its</span><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac"> Supporting information</span></p>
<p style="top:646.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">files.</span></p>
<p style="top:663.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Funding:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> The author(s) received no specific</span></p>
<p style="top:674.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">funding for this work.</span></p>
<p style="top:691.6pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:Arial Narrow,serif;font-size:8.0pt">Competing interests:</span></b><span style="font-family:Arial Narrow,serif;font-size:8.0pt"> The authors have declared</span></p>
<p style="top:702.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt">that no competing interests exist.</span></p>


<p style="top:76.3pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Introduction</span></b></p>
<p style="top:94.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with increasing incidence.</span></p>
<p style="top:107.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">In most cases, pancreatic cancer presents at an advanced stage, with only 20% of all cases</span></p>
<p style="top:120.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">undergoing surgical resection. In terms of prognostic outcomes for patients, pancreatic adeno-</span></p>
<p style="top:133.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">carcinoma ranks last, with an overall 5-year survival rate of 2&#x2013;9% [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">1</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 2</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Even though the man-</span></p>
<p style="top:146.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">agement of pancreatic adenocarcinoma is evolving with the introduction of novel surgical</span></p>
<p style="top:159.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">techniques and medical therapies, only minor improvements in outcomes have been achieved.</span></p>
<p style="top:172.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Due to high resistance, chemotherapy and radiotherapy have limited success in metastatic</span></p>
<p style="top:185.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">PDAC and only marginally prolong patient survival [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">3</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Current treatment options for meta-</span></p>
<p style="top:198.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">static PDAC are modified FOLFIRINOX/FOLFIRINOX or nab-paclitaxel and gemcitabine in</span></p>
<p style="top:211.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">patients with good performance status, and gemcitabine with or without a second agent for</span></p>
<p style="top:224.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">those with poor performance status [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">4</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Most recently, trials studying the update of immuno-</span></p>
<p style="top:237.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">therapy in PDAC were negative except in a subgroup of adenocarcinoma with microsatellite</span></p>
<p style="top:250.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">instability [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">5</span><span style="font-family:MinionPro,serif;font-size:10.0pt">].</span></p>
<p style="top:263.9pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Considering the lack of effective treatment, the identification of novel biomarkers and ther-</span></p>
<p style="top:276.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">apeutic targets is fundamental to developing new treatment strategies and improving clinical</span></p>
<p style="top:289.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">outcomes. Recent studies suggest that signaling pathways involving STAT3 play a key role in</span></p>
<p style="top:302.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">tumorigenesis, progression and drug resistance in several human malignancies such as leuke-</span></p>
<p style="top:315.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">mia, lymphomas as well as solid tumors such as hepatocelullar carcinoma, esophageal, lung,</span></p>
<p style="top:328.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">prostate, bladder and breast cancer [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">6</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 7</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Animal models of PDAC have shown that STAT3 is</span></p>
<p style="top:341.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">an important regulator of stem cell self-renewal and cancer cell survival [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">8</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 9</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Upregulation of</span></p>
<p style="top:354.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">STAT3 has been shown to promote the development of PDAC from pancreatic intraepithelial</span></p>
<p style="top:367.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">neoplasia [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">10</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 11</span><span style="font-family:MinionPro,serif;font-size:10.0pt">], as well as pro-metastatic niche formation in the liver [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">12</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Furthermore,</span></p>
<p style="top:380.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">STAT3 has been shown to mediate resistance to chemotherapy and to be associated with</span></p>
<p style="top:393.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">adverse outcomes following resection of PDAC with curative intent [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">13</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">15</span><span style="font-family:MinionPro,serif;font-size:10.0pt">].</span></p>
<p style="top:406.9pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">As illustrated in</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> Fig 1</span><span style="font-family:MinionPro,serif;font-size:10.0pt">, IL-6-type cytokines (IL-6, IL-10, IL-11, Leukemia inhibitory factor</span></p>
<p style="top:419.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(LIF), Cardiotrophin-1 (CT-1), Oncostatin-M (OSM), Ciliary neurotrophic factor (CNTF)),</span></p>
<p style="top:432.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">bind glycoprotein-130 (GP130) and activate janus kinase (JAK), which in turn phosphorylates</span></p>
<p style="top:445.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">STAT3, among other signaling mediators in PDAC tumor cells as well as cells of tumor micro-</span></p>
<p style="top:458.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">environment (TME) [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">16</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. TME in PDAC is a complex system which consists, along with</span></p>
<p style="top:471.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">extensive stromal networks, of different cell components such as pancreatic stellate cells</span></p>
<p style="top:484.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(PSCs), cancer associated fibroblasts (CAFs), tumor associated macrophages (TAMs), mast</span></p>
<p style="top:497.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">cells, regulatory T-cells and myeloid derived suppressor cells (MDSCs), synergizing to support</span></p>
<p style="top:510.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">tumor progression, immune evasion and metastatic spreading. Interactions between different</span></p>
<p style="top:523.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">cells within the TME are mediated through signaling molecules such as STAT3 activation via</span></p>
<p style="top:536.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">IL-6-type cytokines. For instance, PDAC tumor cells can stimulate immune cells to secrete IL-</span></p>
<p style="top:549.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">6-type cytokines, supporting the development of immunosuppressive TAMs and MDSCs as</span></p>
<p style="top:562.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">well as the activation of PSCs and CAFs, which in turn induce the secretion of inflammatory</span></p>
<p style="top:575.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">cytokines through positive feedback loops [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">11</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 17</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">22</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Thus, STAT3 activation drives immune</span></p>
<p style="top:588.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">cells towards immunosuppressive phenotype by inhibiting regulatory T-cells, which in turn</span></p>
<p style="top:601.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">sustains tumor immune evasion. Furthermore, the phosphorylation of STAT3 leads to</span></p>
<p style="top:614.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">enhanced transcription of downstream target genes, which promote angiogenesis, invasion,</span></p>
<p style="top:627.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">and epithelial-mesenchymal transition (EMT) [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">23</span><span style="font-family:MinionPro,serif;font-size:10.0pt">].</span></p>
<p style="top:640.9pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Accordingly, pathways involving STAT3 appear to be promising drug targets for the treat-</span></p>
<p style="top:653.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">ment of PDAC. In particular, IL-6 has been shown to be a potentially efficient therapeutic</span></p>
<p style="top:666.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">approach for overcoming chemotherapy resistance. The purpose of this study was to provide a</span></p>
<p style="top:679.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">comprehensive summary of therapeutic approaches targeting the GP130/JAK/STAT3 pathway</span></p>
<p style="top:692.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">in pancreatic adenocarcinoma through a systematic qualitative review of the literature.</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2 / 17</span></p>


<p style="top:515.7pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Methods</span></b></p>
<p style="top:534.3pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">This systematic review was performed in accordance with the Preferred Reporting Items for</span></p>
<p style="top:547.3pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Systematic Reviews and Meta-Analyses (PRISMA) [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">24</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Studies were identified by searching</span></p>
<p style="top:560.3pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">PubMed using the following search terms:</span></p>
<p style="top:579.3pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(carcinoma, pancreatic ductal[MeSH Terms]) AND (interleukin-6[MeSH Terms])</span></p>
<p style="top:598.3pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(carcinoma, pancreatic ductal[MeSH Terms]) AND (jak 2 protein tyrosine kinase[MeSH</span></p>
<p style="top:611.3pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Terms])</span></p>
<p style="top:630.3pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(carcinoma, pancreatic ductal[MeSH Terms]) AND (jak 1 protein tyrosine kinase[MeSH</span></p>
<p style="top:643.3pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Terms])</span></p>
<p style="top:662.3pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(carcinoma, pancreatic ductal[Mesh]) AND (stat3 transcription factor[MeSH Terms])</span></p>
<p style="top:681.3pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(carcinoma, pancreatic ductal[MeSH Terms]) AND (gp130, cytokine receptor[MeSH Terms])</span></p>
<p style="top:700.3pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Embase was searched using the following search query:</span></p>
<img style="position:absolute;transform:matrix(.31998009,0,-0,.3199793,-557.3353,-442.56336)" src="data:image/jpeg;base64,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==">
<p style="top:471.2pt;left:94.1pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Fig 1. Schematic presentation of IL-6/JAK/STAT3 pathway in pancreatic cancer cells and tumor microenvironment.</span></b><span style="font-family:MinionPro,serif;font-size:8.0pt"> (PSC: pancreatic stellate cell,</span></p>
<p style="top:480.8pt;left:94.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">CAF: cancer associated fibroblast, TAM: tumor associated macrophages, MDSC: myeloid derived suppressor cells).</span></p>
<p style="top:496.2pt;left:94.1pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1371/journal.pone.0252397.g001</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">3 / 17</span></p>


<p style="top:76.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(&#x2018;pancreas adenocarcinoma&#x2019;/exp OR &#x2018;adenocarcinoma, pancreas&#x2019; OR &#x2018;pancreatic adenocarci-</span></p>
<p style="top:89.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">noma&#x2019; OR &#x2018;pancreatic ductal adenocarcinoma&#x2019;) AND (&#x2018;stat3 protein&#x2019;/exp OR &#x2018;stat3 protein&#x2019;</span></p>
<p style="top:102.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">OR &#x2018;stat3 transcription factor&#x2019; OR &#x2018;protein stat3&#x2019; OR &#x2018;signal transducer and activator of</span></p>
<p style="top:115.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">transcription 3&#x2019; OR &#x2018;stat3&#x2019; OR &#x2018;transcription factor stat3&#x2019;)</span></p>
<p style="top:134.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(&#x2018;pancreas adenocarcinoma&#x2019;/exp AND &#x2018;interleukin 6&#x2019;/exp, filter for articles)</span></p>
<p style="top:153.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(&#x2018;pancreas cancer&#x2019;/exp AND &#x2018;janus kinase 2&#x2019;/exp, filter for articles)</span></p>
<p style="top:172.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(&#x2018;janus kinase 1&#x2019;/exp AND &#x2018;pancreas cancer&#x2019;/exp, filter for articles)</span></p>
<p style="top:191.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(&#x2018;gp130&#x2019;/exp AND &#x2018;pancreas cancer&#x2019;/exp, filter for articles)</span></p>
<p style="top:210.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">The electronic search was supplemented by a manual search of the reference lists of relevant</span></p>
<p style="top:223.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">articles to identify any studies that may have been missed in the database searches. The original</span></p>
<p style="top:236.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">database search was performed on May 5, 2020. The electronic search was updated on October</span></p>
<p style="top:249.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">4, 2020.</span></p>
<p style="top:262.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Inclusion criteria were defined as all trials studying the pharmacological targeting of the</span></p>
<p style="top:275.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">GP130-related cytokine/JAK/STAT3 pathway in pancreatic cancer, including studies on ani-</span></p>
<p style="top:288.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">mal models or cell cultures. Only studies with an English abstract were included. Reviews,</span></p>
<p style="top:301.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">comments, and conference or meeting abstracts were excluded from the analysis. No restric-</span></p>
<p style="top:314.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">tions on publication date or publication status were imposed.</span></p>
<p style="top:327.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">After exclusion of duplicates, records identified from the literature search were screened for</span></p>
<p style="top:340.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">eligibility independently by the two main authors using the title and abstract in an unblinded</span></p>
<p style="top:353.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">manner. Disagreements between the reviewers were resolved by consensus. The full-text of</span></p>
<p style="top:366.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">articles meeting the inclusion criteria was assessed by the two main authors and reevaluated</span></p>
<p style="top:379.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">for the inclusion criteria. Disagreements were, again, resolved by consensus.</span></p>
<p style="top:392.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">We extracted data using a previously prepared extraction form. The information from each</span></p>
<p style="top:405.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">included study on the study design, characteristics of analyzed subjects or trial participants,</span></p>
<p style="top:418.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">characteristics of the pharmacological agent studied, type of outcome measures, and outcomes</span></p>
<p style="top:431.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">was tabulated. On this basis, we performed a qualitative data synthesis.</span></p>
<p style="top:444.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">We performed a quality assessment of clinical trials according to the ROB tool, which was</span></p>
<p style="top:457.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">adapted to match non-randomized clinical trials [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">25</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. For preclinical studies, we used the SYR-</span></p>
<p style="top:470.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">CLE&#x2019;s risk of bias tool, which was adapted to match</span><i><span style="font-family:MinionPro,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:MinionPro,serif;font-size:10.0pt"> and</span><i><span style="font-family:MinionPro,serif;font-size:10.0pt"> in vitro</span></i><span style="font-family:MinionPro,serif;font-size:10.0pt"> studies [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">26</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Results</span></p>
<p style="top:483.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">were displayed in an analogous fashion as suggested by Higgins et al for systematic reviews of</span></p>
<p style="top:496.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">interventions [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">25</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Bias assessment was conducted for every study by two independent asses-</span></p>
<p style="top:509.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">sors and disagreements resolved by consensus.</span></p>
<p style="top:522.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Due to the nature of this study, approval from the local Ethics Committee was not required.</span></p>
<p style="top:560.4pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Results</span></b></p>
<p style="top:578.4pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:MinionPro,serif;font-size:12.0pt">Study selection</span></b></p>
<p style="top:597.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Our search identified 756 records through the database searches (Embase, Pubmed) and the</span></p>
<p style="top:610.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">manual search of the reference lists of relevant articles. Initial screening excluded 689 records,</span></p>
<p style="top:623.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">including 145 duplicates. The remaining 67 articles were assessed based on the full text, 29 of</span></p>
<p style="top:636.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">which were found to be ineligible due to absence of a tested pharmacological substance or the</span></p>
<p style="top:649.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">absence of GP130-related cytokine/JAK/STAT3 pathway targeting.</span></p>
<p style="top:662.0pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">A summary of the study selection process is provided in</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> Fig 2</span><span style="font-family:MinionPro,serif;font-size:10.0pt">. Ultimately, 38 studies were</span></p>
<p style="top:675.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">included in the review, including 4 ongoing trials. All included studies were published in</span></p>
<p style="top:688.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">English and no unpublished data were included. No other studies were identified through the</span></p>
<p style="top:701.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">electronic search update on October 4, 2020.</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">4 / 17</span></p>


<p style="top:356.2pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:MinionPro,serif;font-size:12.0pt">Bias assessment</span></b></p>
<p style="top:374.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">Table 1</span><span style="font-family:MinionPro,serif;font-size:10.0pt"> shows the risk of bias assessment for the preclinical studies. Preclinical studies had</span></p>
<p style="top:387.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">strong limitations to rigorous bias assessment because few provided sufficient details regarding</span></p>
<p style="top:400.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">selection and performance bias. Study protocols were not published beforehand, so a compari-</span></p>
<p style="top:413.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">son between intended interventions and published interventions was not possible. In animal</span></p>
<p style="top:426.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">trials, few studies explicitly stated a randomization process for treatment groups, and treat-</span></p>
<p style="top:439.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">ment results were often assessed manually with semi-quantitative methods. This lack of</span></p>
<p style="top:452.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">reporting makes it difficult to accurately determine the risk of bias of the preclinical studies.</span></p>
<p style="top:465.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">However, more details were available on the risk of attrition bias, reporting bias, and other</span></p>
<p style="top:478.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">bias.</span></p>
<p style="top:491.8pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">The quality assessment of the included clinical trials is provided in</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> Table 2</span><span style="font-family:MinionPro,serif;font-size:10.0pt">. The overall</span></p>
<p style="top:504.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">quality of the studies was good, with only one study presenting high risk of selection bias.</span></p>
<p style="top:539.4pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:MinionPro,serif;font-size:12.0pt">Preclinical studies</span></b></p>
<p style="top:558.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">As summarized in</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> Table 3</span><span style="font-family:MinionPro,serif;font-size:10.0pt">, 25 of the included studies were preclinical trials testing 20 sub-</span></p>
<p style="top:571.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">stances targeting the GP130/JAK/STAT3-pathway. Twenty-four studies performed</span><i><span style="font-family:MinionPro,serif;font-size:10.0pt"> in vitro</span></i></p>
<p style="top:584.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">experiments using human pancreatic cancer cells [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">17</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 27</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">32</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 34</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">36</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 38</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">41</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 43</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">47</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 49</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 50</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 60</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span></p>
<p style="top:597.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">61</span><span style="font-family:MinionPro,serif;font-size:10.0pt">].</span><i><span style="font-family:MinionPro,serif;font-size:10.0pt"> In vivo</span></i><span style="font-family:MinionPro,serif;font-size:10.0pt"> experiments were performed in 17 studies using mouse xenograft tumor models</span></p>
<p style="top:610.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(n = 14) [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">28</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 31</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 34</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 35</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 38</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 40</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">42</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 44</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 45</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 48</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">50</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 60</span><span style="font-family:MinionPro,serif;font-size:10.0pt">], chicken chorio-allantoic membrane</span></p>
<p style="top:623.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">xenograft tumor models (n = 1) [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">32</span><span style="font-family:MinionPro,serif;font-size:10.0pt">], or KPC mice (n = 2) [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">33</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 45</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. All studies reported favor-</span></p>
<p style="top:636.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">able outcomes in terms of pancreatic cancer cell viability, proliferation, migration, colony for-</span></p>
<p style="top:649.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">mation ability, apoptosis, or effects on downstream target genes, as well as tumor growth,</span></p>
<p style="top:662.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">tumor volume, or weight in</span><i><span style="font-family:MinionPro,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:MinionPro,serif;font-size:10.0pt"> models. Eight studies analyzed the combinational effect of</span></p>
<p style="top:675.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">the investigated drug with chemotherapy (i.e., gemcitabine, paclitaxel, 5-fluorouracil, and oxa-</span></p>
<p style="top:688.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">liplatin) [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">31</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 33</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 38</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 40</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 41</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 45</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 49</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 60</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. In all studies, the inhibitory effect on pancreatic cancer</span></p>
<p style="top:701.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">cells by the investigated drug was enhanced by chemotherapy.</span></p>
<img style="position:absolute;transform:matrix(.31997467,0,-0,.31997306,-73.32864,-215.59932)" src="data:image/jpeg;base64,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==">
<p style="top:310.7pt;left:200.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Fig 2. PRISMA flow chart of included studies.</span></b></p>
<p style="top:326.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1371/journal.pone.0252397.g002</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">5 / 17</span></p>


<p style="top:702.9pt;left:34.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Table 1. Bias assessment of preclinical studies.</span></b></p>
<p style="top:704.5pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Reference</span></b></p>
<p style="top:667.3pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Chen</span></b></p>
<p style="top:666.6pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2019</span></b></p>
<p style="top:645.9pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Edderkaoui</span></b></p>
<p style="top:637.9pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2013</span></b></p>
<p style="top:608.3pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Fu</span></b></p>
<p style="top:610.8pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2018</span></b></p>
<p style="top:590.0pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Ge</span></b></p>
<p style="top:592.3pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2015</span></b></p>
<p style="top:573.0pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Goumas</span></b></p>
<p style="top:568.9pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2015</span></b></p>
<p style="top:543.7pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Lin</span></b></p>
<p style="top:545.4pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2010</span></b></p>
<p style="top:526.0pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Long</span></b></p>
<p style="top:525.6pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2017</span></b></p>
<p style="top:505.1pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Palagani</span></b></p>
<p style="top:500.6pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2014</span></b></p>
<p style="top:476.0pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Sahu</span></b></p>
<p style="top:475.8pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2017</span></b></p>
<p style="top:455.0pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Sun</span></b></p>
<p style="top:456.1pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2009</span></b></p>
<p style="top:436.6pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Thoennissen</span></b></p>
<p style="top:427.4pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2009</span></b></p>
<p style="top:397.6pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Wu</span></b></p>
<p style="top:398.8pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2016</span></b></p>
<p style="top:379.4pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Zhang</span></b></p>
<p style="top:377.5pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2018</span></b></p>
<p style="top:355.4pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Nagaraju</span></b></p>
<p style="top:350.3pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2016</span></b></p>
<p style="top:324.9pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Nagaraju</span></b></p>
<p style="top:319.7pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2019</span></b></p>
<p style="top:294.4pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Chen</span></b></p>
<p style="top:293.8pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2016</span></b></p>
<p style="top:271.4pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Lu</span></b></p>
<p style="top:273.9pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2019</span></b></p>
<p style="top:253.7pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Liu</span></b></p>
<p style="top:255.3pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2011</span></b></p>
<p style="top:235.9pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Huang</span></b></p>
<p style="top:233.6pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2016</span></b></p>
<p style="top:210.8pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Luo</span></b></p>
<p style="top:211.8pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2019</span></b></p>
<p style="top:192.3pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Kim</span></b></p>
<p style="top:192.7pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2016</span></b></p>
<p style="top:173.1pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Venkatasubbara</span></b></p>
<p style="top:159.7pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2005</span></b></p>
<p style="top:124.6pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Lu</span></b></p>
<p style="top:127.1pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2017</span></b></p>
<p style="top:107.0pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Liu</span></b></p>
<p style="top:108.6pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2019</span></b></p>
<p style="top:89.2pt;left:52.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">Song</span></b></p>
<p style="top:89.0pt;left:59.5pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">2018</span></b></p>
<p style="top:665.8pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">27</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:637.1pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">28</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:610.0pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">29</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:591.5pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">30</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:568.1pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">31</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:544.6pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">32</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:524.8pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">33</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:499.8pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">34</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:475.0pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">35</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:455.3pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">36</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:426.6pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">37</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:398.0pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">38</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:376.7pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">39</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:349.5pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">40</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:318.9pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">41</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:293.0pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">17</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:273.1pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">42</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:254.5pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">43</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:232.8pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">44</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:211.0pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">45</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:191.9pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">46</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:158.9pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">47</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:126.3pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">48</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:107.8pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">49</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:88.2pt;left:69.6pt;line-height:5.5pt"><b><span style="font-family:MinionPro,serif;font-size:5.5pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt;color:#3c64ac">50</span></b><b><span style="font-family:MinionPro,serif;font-size:5.5pt">]</span></b></p>
<p style="top:662.8pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:634.1pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:607.0pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:588.5pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:565.0pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:541.4pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:522.1pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">V</span></p>
<p style="top:496.7pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:471.9pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:452.3pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:423.6pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:394.9pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:373.7pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:346.4pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:315.9pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:290.0pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:270.3pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">V</span></p>
<p style="top:251.5pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:229.7pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:207.9pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:188.9pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:155.9pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:123.3pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">T</span></p>
<p style="top:104.7pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:85.1pt;left:79.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">B</span></p>
<p style="top:704.5pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">1) Selection</span></p>
<p style="top:663.0pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:634.5pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:607.1pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:588.7pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:565.4pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:541.9pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:522.2pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:496.9pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:472.3pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:452.4pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:424.0pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:395.1pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:373.8pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:346.6pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:316.3pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:290.1pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:270.2pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:251.6pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:229.9pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:208.3pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:189.1pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:156.0pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:123.4pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:105.2pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:85.6pt;left:89.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:704.5pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">2)</span></p>
<p style="top:704.5pt;left:106.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">Performance</span></p>
<p style="top:663.0pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:634.2pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:607.1pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:588.7pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:565.2pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:541.7pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:521.9pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:496.9pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:472.1pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:452.4pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:423.7pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:395.1pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:373.8pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:346.6pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:316.0pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:290.1pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:270.2pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:251.6pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:229.9pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:208.1pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:189.1pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:156.0pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:123.4pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:104.9pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:85.3pt;left:99.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:704.5pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">3) Detection</span></p>
<p style="top:662.9pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:634.2pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:607.3pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:588.9pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:565.2pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:541.7pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:521.9pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:496.9pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:472.1pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:452.7pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:423.7pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:395.2pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:374.0pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:346.6pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:316.3pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:290.1pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:270.2pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:251.6pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:229.9pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">X</span></p>
<p style="top:208.1pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:189.3pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:156.3pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:123.7pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:105.2pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:85.4pt;left:116.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">//</span></p>
<p style="top:704.5pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">4) Reporting</span></p>
<p style="top:663.2pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:634.5pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:607.3pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:588.9pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:565.4pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:541.9pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:522.2pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:497.2pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:472.3pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:452.7pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:424.0pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:395.4pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:374.0pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:346.8pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:316.3pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:290.4pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:270.4pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:251.9pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:230.1pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:208.3pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:189.3pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:156.3pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:123.7pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:105.2pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:85.6pt;left:126.6pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:704.5pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">5) Other</span></p>
<p style="top:663.2pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:634.5pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:607.3pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:588.9pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:565.4pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:541.9pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:522.2pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:497.2pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:472.3pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:452.7pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:424.0pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:395.4pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:374.0pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:346.8pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:316.3pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:290.4pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:270.4pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:251.9pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:230.1pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:208.3pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:189.3pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:156.3pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:123.7pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:105.2pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:85.6pt;left:136.5pt;line-height:5.5pt"><span style="font-family:MinionPro,serif;font-size:5.5pt">O</span></p>
<p style="top:702.5pt;left:153.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">1) Was the allocation sequence adequately generated, applied, and concealed? Were the groups similar at baseline or were they adjusted for confounders?</span></p>
<p style="top:702.5pt;left:165.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2) Were the caregivers and/or investigators blinded from knowledge of which intervention each animal received during the experiment?</span></p>
<p style="top:702.5pt;left:177.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">3) Were animals/cell cultures selected at random for outcome assessment? Was the outcome assessor blinded? Was a computed/automatic tool used?</span></p>
<p style="top:702.5pt;left:189.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">4) Are reports of the study free of selective outcome reporting?</span></p>
<p style="top:702.5pt;left:201.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">5) Was the study apparently free of other problems that could result in high risk of bias?</span></p>
<p style="top:702.5pt;left:213.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">V: In vivo study T: in vitro study B: in vivo and in vitro</span></p>
<p style="top:702.5pt;left:225.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O Meets criteria (low risk of biais) // Some concerns (unclear risk of bias, insufficient reporting) X Does not meet criteria (high risk of bias)</span></p>
<p style="top:702.9pt;left:240.4pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1371/journal.pone.0252397.t001</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">6 / 17</span></p>


<p style="top:485.2pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:MinionPro,serif;font-size:12.0pt">Clinical studies</span></b></p>
<p style="top:503.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">As summarized in</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> Table 4</span><span style="font-family:MinionPro,serif;font-size:10.0pt">, nine of the studies were clinical trials including 880 individuals and</span></p>
<p style="top:516.7pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">assessing 5 drugs. One study performed a retrospective analysis of bazedoxifene, an inhibitor</span></p>
<p style="top:529.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">of the IL-6/IL-6R/GP130 complex, in patients with pancreatic (n = 5) or gastric adenocarci-</span></p>
<p style="top:542.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">noma (n = 2), showing biological tumor marker reduction in 80% and disease regression on</span></p>
<p style="top:555.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">PET-CT in 60% of cases [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">51</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Icatinib, a selective JAK1 inhibitor, was tested in combination</span></p>
<p style="top:568.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">with nab-paclitaxel and gemcitabine, showing a synergistic effect with an overall response rate</span></p>
<p style="top:581.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">of 24% with an acceptable safety profile in a phase 1b/2 study [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">52</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. However, this study was ter-</span></p>
<p style="top:594.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">minated early due to negative phase 3 results for JAK1/2 inhibitor ruxolitinib [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">55</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Momeloti-</span></p>
<p style="top:607.7pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">nib, a JAK1/2 inhibitor, resulted in a partial response in 28% of patients with previously</span></p>
<p style="top:620.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">untreated metastatic PDAC (n = 25) in a phase 1 study. However, no significant difference was</span></p>
<p style="top:633.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">reported from treatment with paclitaxel and gemcitabine [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">53</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Ruxolitinib, a JAK1/2 inhibitor,</span></p>
<p style="top:646.7pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">has been investigated in phase 1b, 2, and 3 clinical trials in combination with capecitabine,</span></p>
<p style="top:659.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">gemcitabine, and paclitaxel, revealing no significant difference in overall survival or progres-</span></p>
<p style="top:672.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">sion-free survival in patients with PDAC [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">54</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">56</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Finally, phase 2 and 3 studies have been per-</span></p>
<p style="top:685.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">formed assessing tipifarnib, an inhibitor of STAT3 phosphorylation that showed no single-</span></p>
<p style="top:698.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">agent antitumor activity and no difference in overall survival in combination with gemcitabine</span></p>
<p style="top:76.9pt;left:200.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Table 2. Bias assessment of the clinical studies.</span></b></p>
<p style="top:91.7pt;left:200.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Reference</span></b></p>
<p style="top:91.7pt;left:257.2pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Burkhardt</span></b></p>
<p style="top:101.2pt;left:257.2pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2019</span></b></p>
<p style="top:91.7pt;left:301.9pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Beatty</span></b></p>
<p style="top:101.2pt;left:301.9pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2019</span></b></p>
<p style="top:91.7pt;left:332.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Ng</span></b></p>
<p style="top:101.2pt;left:332.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2019</span></b></p>
<p style="top:91.7pt;left:356.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Bauer</span></b></p>
<p style="top:101.2pt;left:356.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2018</span></b></p>
<p style="top:91.7pt;left:385.3pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Hurwitz</span></b></p>
<p style="top:101.2pt;left:385.3pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2018</span></b></p>
<p style="top:91.7pt;left:422.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Hurwitz</span></b></p>
<p style="top:101.2pt;left:422.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2015</span></b></p>
<p style="top:91.7pt;left:460.1pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Eckhardt</span></b></p>
<p style="top:101.2pt;left:460.1pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2009</span></b></p>
<p style="top:91.7pt;left:500.1pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Macdonald</span></b></p>
<p style="top:101.2pt;left:500.1pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2005</span></b></p>
<p style="top:91.7pt;left:547.2pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Cohen</span></b></p>
<p style="top:101.2pt;left:547.2pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">2003</span></b></p>
<p style="top:113.7pt;left:270.5pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">51</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:113.7pt;left:308.3pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">52</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:113.7pt;left:335.3pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">53</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:113.7pt;left:361.6pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">54</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:113.7pt;left:395.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">55</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:113.7pt;left:432.3pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">56</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:113.7pt;left:471.1pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">57</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:113.7pt;left:514.6pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">58</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:113.7pt;left:553.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">59</span></b><b><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></b></p>
<p style="top:126.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Design Phase</span></p>
<p style="top:126.2pt;left:274.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">R</span></p>
<p style="top:126.2pt;left:312.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">P</span></p>
<p style="top:126.2pt;left:339.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">P</span></p>
<p style="top:126.2pt;left:366.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">P</span></p>
<p style="top:126.2pt;left:399.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">P</span></p>
<p style="top:126.2pt;left:436.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">P</span></p>
<p style="top:126.2pt;left:475.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">P</span></p>
<p style="top:126.2pt;left:519.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">P</span></p>
<p style="top:126.2pt;left:558.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">P</span></p>
<p style="top:138.7pt;left:307.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ib/II</span></p>
<p style="top:138.7pt;left:340.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">I</span></p>
<p style="top:138.7pt;left:365.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ib</span></p>
<p style="top:138.7pt;left:397.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">III</span></p>
<p style="top:138.7pt;left:436.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">II</span></p>
<p style="top:138.7pt;left:473.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">III</span></p>
<p style="top:138.7pt;left:518.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">II</span></p>
<p style="top:138.7pt;left:557.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">II</span></p>
<p style="top:151.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">1) Selection</span></p>
<p style="top:160.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">process</span></p>
<p style="top:151.2pt;left:274.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">X</span></p>
<p style="top:151.2pt;left:312.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">//</span></p>
<p style="top:151.2pt;left:339.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">//</span></p>
<p style="top:151.2pt;left:365.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">//</span></p>
<p style="top:151.2pt;left:398.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:151.2pt;left:436.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:151.2pt;left:474.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:151.2pt;left:518.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:151.2pt;left:557.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2) Deviation</span></p>
<p style="top:182.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">from intended</span></p>
<p style="top:192.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">intervention</span></p>
<p style="top:173.2pt;left:274.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:312.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:339.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:365.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:398.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:436.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:474.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:518.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:173.2pt;left:557.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">3) Missing</span></p>
<p style="top:214.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">outcome data</span></p>
<p style="top:204.7pt;left:274.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:312.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:339.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:365.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:398.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:436.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:474.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:518.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:204.7pt;left:557.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:226.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">4)</span></p>
<p style="top:236.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Measurement</span></p>
<p style="top:245.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">of the outcome</span></p>
<p style="top:226.7pt;left:274.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">//</span></p>
<p style="top:226.7pt;left:312.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:226.7pt;left:339.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:226.7pt;left:365.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:226.7pt;left:398.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:226.7pt;left:436.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:226.7pt;left:474.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:226.7pt;left:518.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:226.7pt;left:557.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">5) Selection of</span></p>
<p style="top:267.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">the reported</span></p>
<p style="top:277.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">result</span></p>
<p style="top:258.2pt;left:274.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:312.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:339.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:365.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:398.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:436.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:474.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:518.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:258.2pt;left:557.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:289.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">6) Overall</span></p>
<p style="top:289.7pt;left:274.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">//</span></p>
<p style="top:289.7pt;left:312.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:289.7pt;left:339.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:289.7pt;left:365.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:289.7pt;left:398.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:289.7pt;left:436.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:289.7pt;left:474.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:289.7pt;left:518.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:289.7pt;left:557.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O</span></p>
<p style="top:308.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">1) Does the patient(s) represent(s) the whole experience of the investigator? Is the selection method clear? Was the</span></p>
<p style="top:320.4pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">allocation sequence random?</span></p>
<p style="top:332.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2) Did the investigator deviate from intended interventions? Were investigators/study participants blinded?</span></p>
<p style="top:344.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">3) Is there evidence that the result was not biased by missing outcome data? Were incomplete outcome data</span></p>
<p style="top:356.4pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">adequately addressed?</span></p>
<p style="top:368.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">4) Was the method of measuring the outcome (in)appropriate? Could measurement or ascertainment of the outcome</span></p>
<p style="top:380.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">have differed between intervention groups?</span></p>
<p style="top:392.4pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">5) Were the data that produced this result analyzed in accordance with a pre-specified analysis plan?</span></p>
<p style="top:404.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">6) Was the study apparently free of other problems that could result in high risk of bias?</span></p>
<p style="top:416.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">R: retrospective P: prospective</span></p>
<p style="top:428.4pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">O Meets criteria (low risk of bias) // Some concerns (unclear risk of bias, insufficient reporting) X Does not meet</span></p>
<p style="top:440.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">criteria (high risk of bias)</span></p>
<p style="top:458.5pt;left:200.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1371/journal.pone.0252397.t002</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">7 / 17</span></p>


<p style="top:76.9pt;left:36.9pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Table 3. Characteristics of the included preclinical studies.</span></b></p>
<p style="top:91.7pt;left:36.9pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Reference</span></b></p>
<p style="top:91.7pt;left:123.6pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:101.2pt;left:123.6pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">design</span></b></p>
<p style="top:91.7pt;left:156.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Drug</span></b></p>
<p style="top:91.7pt;left:235.6pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Mechanism of action</span></b></p>
<p style="top:91.7pt;left:322.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Subject</span></b></p>
<p style="top:91.7pt;left:383.4pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Number</span></b></p>
<p style="top:91.7pt;left:417.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Outcome</span></b></p>
<p style="top:113.7pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Zhang 2018</span></p>
<p style="top:113.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">39</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:113.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:113.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">AG490 (Tyrphostin</span></p>
<p style="top:123.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">B42)</span></p>
<p style="top:113.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK2/STAT3 inhibition</span></p>
<p style="top:113.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:113.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:113.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell viability,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 overexpression and</span></p>
<p style="top:123.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation, downregulation of target</span></p>
<p style="top:132.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">genes</span></p>
<p style="top:145.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Palagani 2014</span></p>
<p style="top:145.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">34</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:145.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:145.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">AG490</span></p>
<p style="top:145.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK2/STAT3 inhibition</span></p>
<p style="top:145.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:145.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:145.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis</span></p>
<p style="top:157.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:157.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ GSI IX</span></p>
<p style="top:157.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Notch (Hes1)</span></p>
<p style="top:167.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">inhibition</span></p>
<p style="top:157.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:157.7pt;left:404.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">20</span></p>
<p style="top:157.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor growth</span></p>
<p style="top:179.7pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Wu 2016</span></p>
<p style="top:179.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">38</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:179.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:179.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Bazedoxifene</span></p>
<p style="top:179.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibitor of IL-6/IL-6R/</span></p>
<p style="top:189.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">GP130 complex</span></p>
<p style="top:179.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:179.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:179.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation,</span></p>
<p style="top:189.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">downregulation of target genes,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell migration</span></p>
<p style="top:201.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:201.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Pac</span></p>
<p style="top:201.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:201.7pt;left:408.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">8</span></p>
<p style="top:201.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor growth, enhanced effect with</span></p>
<p style="top:211.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Pac</span></p>
<p style="top:223.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Gem</span></p>
<p style="top:223.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">No significant toxicity</span></p>
<p style="top:236.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Fu 2018</span></p>
<p style="top:236.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">29</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:236.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:236.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Bazedoxifene</span></p>
<p style="top:236.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibitor of IL-6/IL-6R/</span></p>
<p style="top:245.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">GP130 complex</span></p>
<p style="top:236.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:236.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:236.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell viability,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell migration,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> colony</span></p>
<p style="top:245.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">formation Enhanced effect with combinational</span></p>
<p style="top:255.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">therapy</span></p>
<p style="top:248.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ reparixine</span></p>
<p style="top:261.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ SCH527123</span></p>
<p style="top:273.7pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Chen 2019</span></p>
<p style="top:273.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">27</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:273.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:273.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Bazedoxifene</span></p>
<p style="top:273.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibitor of IL-6/IL-6R/</span></p>
<p style="top:283.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">GP130 complex</span></p>
<p style="top:273.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:273.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:273.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell viability,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> colony</span></p>
<p style="top:283.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">formation</span></p>
<p style="top:295.7pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ge 2015</span></p>
<p style="top:295.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">30</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:295.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:295.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Cryptotanshinone</span></p>
<p style="top:295.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 inhibition</span></p>
<p style="top:295.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:295.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:295.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">&quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis, downregulation of target genes</span></p>
<p style="top:308.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Thoennissen 2009</span></p>
<p style="top:308.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">37</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:308.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:308.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Cucurbitacin B</span></p>
<p style="top:308.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of</span></p>
<p style="top:317.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation of JAK2</span></p>
<p style="top:327.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">and STAT3</span></p>
<p style="top:308.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:308.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:308.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis,</span></p>
<p style="top:317.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">enhanced effect with combinational therapy</span></p>
<p style="top:330.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:330.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Gem</span></p>
<p style="top:330.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:330.2pt;left:408.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">5</span></p>
<p style="top:330.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor volume,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor weight</span></p>
<p style="top:342.7pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Sun 2009</span></p>
<p style="top:342.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">62</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:342.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:342.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Cucurbitacin E</span></p>
<p style="top:342.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of STAT3</span></p>
<p style="top:352.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:342.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:342.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:342.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis</span></p>
<p style="top:364.7pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Edderkaoui 2013</span></p>
<p style="top:364.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">28</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:364.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:364.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ellagic acid</span></p>
<p style="top:364.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">1) Inhibition of STAT3</span></p>
<p style="top:374.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:364.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:364.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:364.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis by embelin</span></p>
<p style="top:386.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:386.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Embelin</span></p>
<p style="top:386.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2) inhibition of NF-kB</span></p>
<p style="top:386.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:386.7pt;left:404.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">24</span></p>
<p style="top:386.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Enhanced effect with combinational therapy</span></p>
<p style="top:399.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Lin 2010</span></p>
<p style="top:399.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">32</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:399.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:399.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">FLLL31</span></p>
<p style="top:399.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Selective inhibition of</span></p>
<p style="top:408.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK2/STAT3(SH2)</span></p>
<p style="top:399.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:399.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:399.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation,</span></p>
<p style="top:408.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">downregulation of target genes,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis</span></p>
<p style="top:421.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:421.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">FLLL 32</span></p>
<p style="top:421.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Chorio-allantoic</span></p>
<p style="top:430.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">membrane XTM</span></p>
<p style="top:421.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:421.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor volume,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> neo-angiogenesis</span></p>
<p style="top:443.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Nagaraju 2016</span></p>
<p style="top:443.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">40</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:443.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:443.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ganetispib</span></p>
<p style="top:443.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HSP90 und JAK2</span></p>
<p style="top:452.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">inhibition</span></p>
<p style="top:443.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:443.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:443.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation</span></p>
<p style="top:455.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:455.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Gem/Pac</span></p>
<p style="top:455.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:455.7pt;left:404.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">35</span></p>
<p style="top:455.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor growth, enhanced effect with</span></p>
<p style="top:465.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">combinational therapy</span></p>
<p style="top:468.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ 5-FU/Ox</span></p>
<p style="top:480.7pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Nagaraju 2019</span></p>
<p style="top:480.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">41</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:480.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:480.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ganetispib</span></p>
<p style="top:480.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HSP90 und JAK2</span></p>
<p style="top:490.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">inhibition</span></p>
<p style="top:480.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:480.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:480.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> VEGF</span></p>
<p style="top:493.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:493.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ 5-FU</span></p>
<p style="top:493.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:493.2pt;left:404.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">16</span></p>
<p style="top:493.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo: enhanced effect with combinational</span></p>
<p style="top:502.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">therapy, no significant toxicity</span></p>
<p style="top:515.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Lu 2019</span></p>
<p style="top:515.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">42</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:515.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:515.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">IL-9 antibody</span></p>
<p style="top:515.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of IL-9</span></p>
<p style="top:515.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:515.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:515.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> VEGF</span></p>
<p style="top:527.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:527.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:527.7pt;left:404.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">48</span></p>
<p style="top:527.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor weight,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> survival</span></p>
<p style="top:540.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Chen 2016</span></p>
<p style="top:540.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">17</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:540.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:540.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Interleukin 32</span><span style="font-family:SymbolGreekU,serif;font-size:8.0pt">&#x3b1;</span></p>
<p style="top:540.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of JAK2/</span></p>
<p style="top:549.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3</span></p>
<p style="top:540.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:540.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:540.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Downregulation of target genes</span></p>
<p style="top:562.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Liu 2011</span></p>
<p style="top:562.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">43</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:562.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:562.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">LLL12</span></p>
<p style="top:562.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Blocking of IL-</span></p>
<p style="top:571.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">6-induced STAT3</span></p>
<p style="top:581.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:562.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:562.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:562.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt">cell viability</span></p>
<p style="top:593.7pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Huang 2016</span></p>
<p style="top:593.7pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">44</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:593.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:593.7pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">LTP-1</span></p>
<p style="top:593.7pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 inhibitor</span></p>
<p style="top:593.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:593.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:593.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell viability,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span></p>
<p style="top:603.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">apoptosis</span></p>
<p style="top:615.7pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:615.7pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:615.7pt;left:404.7pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">40</span></p>
<p style="top:615.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor growth</span></p>
<p style="top:628.2pt;left:36.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Kim 2016</span></p>
<p style="top:628.2pt;left:104.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">46</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:628.2pt;left:124.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:628.2pt;left:157.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Morusin</span></p>
<p style="top:628.2pt;left:236.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 inhibitor</span></p>
<p style="top:628.2pt;left:323.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:628.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:628.2pt;left:418.8pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 phosphorylation, downregulation of</span></p>
<p style="top:637.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">target genes,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis</span></p>
<p style="top:652.2pt;left:537.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(</span><i><span style="font-family:MinionPro,serif;font-size:8.0pt">Continued</span></i><span style="font-family:MinionPro,serif;font-size:8.0pt">)</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">8 / 17</span></p>


<p style="top:549.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">[</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">57</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">59</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Four ongoing clinical trials were found, involving tocilizumab, an anti-IL6R</span><span style="font-family:SymbolGreekU,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:MinionPro,serif;font-size:10.0pt"> anti-</span></p>
<p style="top:561.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">body with favorable results in preclinical studies [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">31</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 33</span><span style="font-family:MinionPro,serif;font-size:10.0pt">], and napabucasin, a STAT3 inhibitor</span></p>
<p style="top:575.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">that is also under investigation in colorectal cancer [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">63</span><span style="font-family:MinionPro,serif;font-size:10.0pt">].</span></p>
<p style="top:604.4pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Discussion</span></b></p>
<p style="top:623.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">The present systematic review of 25 preclinical studies and 9 clinical trials revealed a good</span></p>
<p style="top:636.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">overall effect of the investigated drugs targeting the GP130/JAK/STAT3 pathway in the treat-</span></p>
<p style="top:649.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">ment of PDAC.</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> Table 5</span><span style="font-family:MinionPro,serif;font-size:10.0pt"> summarizes the outcome and the state of research for each assessed</span></p>
<p style="top:662.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">drug. Favorable outcomes have been reported for all 20 drugs investigated in a preclinical set-</span></p>
<p style="top:675.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">ting. Even though these substances appear promising in the treatment of PDAC, only five of</span></p>
<p style="top:688.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">these drugs have been investigated in clinical trials. Favorable outcomes and acceptable toxicity</span></p>
<p style="top:701.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">profiles have been found in studies investigating bazedoxifene and itacitinib [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">51</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 52</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Notably,</span></p>
<p style="top:77.1pt;left:35.4pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Table 3.</span></b><span style="font-family:MinionPro,serif;font-size:8.0pt"> (Continued)</span></p>
<p style="top:94.6pt;left:35.4pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Reference</span></b></p>
<p style="top:94.6pt;left:122.2pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Study</span></b></p>
<p style="top:104.1pt;left:122.2pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">design</span></b></p>
<p style="top:94.6pt;left:155.4pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Drug</span></b></p>
<p style="top:94.6pt;left:234.2pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Mechanism of action</span></b></p>
<p style="top:94.6pt;left:321.3pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Subject</span></b></p>
<p style="top:94.6pt;left:381.9pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Number</span></b></p>
<p style="top:94.6pt;left:416.4pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Outcome</span></b></p>
<p style="top:116.6pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Luo 2019</span></p>
<p style="top:116.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">45</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:116.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:116.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phospho-valproic acid</span></p>
<p style="top:126.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(MDC-1112)</span></p>
<p style="top:116.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:116.6pt;left:408.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:116.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> colony formation,</span></p>
<p style="top:138.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:138.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Gem</span></p>
<p style="top:151.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ 5-FU</span></p>
<p style="top:151.1pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:151.1pt;left:403.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">16</span></p>
<p style="top:151.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> invasion,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis with combinational</span></p>
<p style="top:160.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">therapy</span></p>
<p style="top:173.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ abraxane</span></p>
<p style="top:173.1pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">KPC mice</span></p>
<p style="top:173.1pt;left:403.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">30</span></p>
<p style="top:173.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation,</span></p>
<p style="top:182.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">downregulation of target genes,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor growth</span></p>
<p style="top:192.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">with Gem</span></p>
<p style="top:204.6pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Sahu 2017</span></p>
<p style="top:204.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">35</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:204.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:204.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">1) Ponatinib</span></p>
<p style="top:204.6pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">1) Multi-receptor</span></p>
<p style="top:214.1pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">tyrosine kinase inhibitor</span></p>
<p style="top:204.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:204.6pt;left:408.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:204.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation</span></p>
<p style="top:226.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:226.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2) Cobemetinib</span></p>
<p style="top:226.6pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2) MEK inhibitor</span></p>
<p style="top:226.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:226.6pt;left:403.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">80</span></p>
<p style="top:226.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo: -</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor growth,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis with</span></p>
<p style="top:236.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">combinational therapy, safety issues (weight</span></p>
<p style="top:245.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">loss)</span></p>
<p style="top:258.1pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Lu 2017</span></p>
<p style="top:258.1pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">48</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:258.1pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:258.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ruxolitinib</span></p>
<p style="top:258.1pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK1/2 inhibitor</span></p>
<p style="top:258.1pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:258.1pt;left:408.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:258.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> T cell proliferation</span></p>
<p style="top:270.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:270.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:270.6pt;left:403.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">30</span></p>
<p style="top:270.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cytotoxic</span></p>
<p style="top:280.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">T-lymphocyte infiltration and activation</span></p>
<p style="top:292.6pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Liu 2019</span></p>
<p style="top:292.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">49</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:292.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:292.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">S-Adenosyl-</span></p>
<p style="top:302.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">methionine (SAM)</span></p>
<p style="top:292.6pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of JAK2/</span></p>
<p style="top:302.1pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3</span></p>
<p style="top:292.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:292.6pt;left:408.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:292.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span></p>
<p style="top:302.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">invasion</span></p>
<p style="top:314.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:314.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Gem</span></p>
<p style="top:314.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:314.6pt;left:403.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">24</span></p>
<p style="top:314.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor weight,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor volume,</span></p>
<p style="top:324.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">enhanced effect with combinational therapy</span></p>
<p style="top:336.6pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Song 2018</span></p>
<p style="top:336.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">50</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:336.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:336.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">SZC015 (oleanolic</span></p>
<p style="top:346.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">acid derivative)</span></p>
<p style="top:336.6pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Suppression of NF</span><span style="font-family:SymbolGreekU,serif;font-size:8.0pt">&#x3ba;</span><span style="font-family:MinionPro,serif;font-size:8.0pt">B</span></p>
<p style="top:346.1pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">and JAK2/STAT3</span></p>
<p style="top:336.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:336.6pt;left:408.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:336.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell viability</span></p>
<p style="top:349.1pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:349.1pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:349.1pt;left:403.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">15</span></p>
<p style="top:349.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> JAK2/STAT3 signaling,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> &quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis</span></p>
<p style="top:361.6pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Venkatasubbarao</span></p>
<p style="top:371.1pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2005</span></p>
<p style="top:361.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">47</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:361.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:361.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tipifarnib (R1115777)</span></p>
<p style="top:361.6pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of STAT3</span></p>
<p style="top:371.1pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:361.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:361.6pt;left:408.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:361.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation</span></p>
<p style="top:383.6pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Goumas 2015</span></p>
<p style="top:383.6pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">31</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:383.6pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro</span></p>
<p style="top:383.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tocilizumab</span></p>
<p style="top:383.6pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">1) Anti-IL6R</span><span style="font-family:SymbolGreekU,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:MinionPro,serif;font-size:8.0pt">,</span></p>
<p style="top:393.1pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">humanized monoclonal</span></p>
<p style="top:402.6pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">antibody</span></p>
<p style="top:383.6pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC</span></p>
<p style="top:383.6pt;left:408.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:383.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vitro:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation</span></p>
<p style="top:415.1pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:415.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2) sgp130Fc</span></p>
<p style="top:415.1pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2) GP130 inhibitor</span></p>
<p style="top:415.1pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Mouse XTM</span></p>
<p style="top:415.1pt;left:403.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">40</span></p>
<p style="top:415.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo:</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor growth,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> neoangiogenesis, no</span></p>
<p style="top:424.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">enhanced effect with Gem,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> tumor recurrence</span></p>
<p style="top:434.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">and metastasis as adjuvant treatment after</span></p>
<p style="top:443.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">surgery</span></p>
<p style="top:427.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Gem</span></p>
<p style="top:440.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ surgery</span></p>
<p style="top:456.1pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Long 2017</span></p>
<p style="top:456.1pt;left:103.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">33</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:456.1pt;left:123.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">In vivo</span></p>
<p style="top:456.1pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tocilizumab</span></p>
<p style="top:456.1pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Anti-IL6R</span><span style="font-family:SymbolGreekU,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:MinionPro,serif;font-size:8.0pt">, humanized</span></p>
<p style="top:465.6pt;left:235.2pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">monoclonal antibody</span></p>
<p style="top:456.1pt;left:322.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">KPC mice</span></p>
<p style="top:456.1pt;left:408.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">-</span></p>
<p style="top:456.1pt;left:417.4pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">#</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> STAT3 phosphorylation,</span><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt"> #</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> cell proliferation,</span></p>
<p style="top:468.6pt;left:156.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ Gem</span></p>
<p style="top:468.6pt;left:417.4pt;line-height:8.0pt"><span style="font-family:TeX_CM_Maths_Symbols,serif;font-size:8.0pt">&quot;</span><span style="font-family:MinionPro,serif;font-size:8.0pt"> apoptosis, enhanced effect with Gem</span></p>
<p style="top:487.3pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HPCC: human pancreatic cancer cell, PDAC: pancreatic ductal adenocarcinoma, XTM: xenograft tumor model, Ox: oxaliplatin, Gem: gemcitabine, Pac: paclitaxel,</span></p>
<p style="top:499.4pt;left:35.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">5-FU: 5-fluorouracil,&#x2014;indicates no data available</span></p>
<p style="top:517.3pt;left:35.4pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1371/journal.pone.0252397.t003</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:557.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">9 / 17</span></p>


<p style="top:624.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">bazedoxifene is already approved for the treatment of osteoporosis [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">64</span><span style="font-family:MinionPro,serif;font-size:10.0pt">], and itacitinib has</span></p>
<p style="top:637.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">been shown to have great potential in recent clinical trials studying the treatment of connective</span></p>
<p style="top:650.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">tissue diseases and graft-versus-host disease, among others [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">65</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">67</span><span style="font-family:MinionPro,serif;font-size:10.0pt">].</span></p>
<p style="top:663.9pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Even though the PDAC tumor micro-environment (TME) has been shown to be a promis-</span></p>
<p style="top:676.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">ing target for improving PDAC treatment, none of the included studies in this systematic</span></p>
<p style="top:689.9pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">review examined the influence of the analyzed substances on stromal or immune cells.</span></p>
<p style="top:76.9pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Table 4. Characteristics of included clinical studies.</span></b></p>
<p style="top:91.7pt;left:36.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Reference</span></b></p>
<p style="top:91.7pt;left:104.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Study design</span></b></p>
<p style="top:91.7pt;left:170.1pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Drug</span></b></p>
<p style="top:91.7pt;left:229.4pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Mechanism of action</span></b></p>
<p style="top:91.7pt;left:311.2pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Subject</span></b></p>
<p style="top:91.7pt;left:410.6pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Number</span></b></p>
<p style="top:91.7pt;left:445.1pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Outcome</span></b></p>
<p style="top:104.2pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Burkhardt</span></p>
<p style="top:113.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2019</span></p>
<p style="top:104.2pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">51</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:104.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Retrospective</span></p>
<p style="top:104.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Bazedoxifene</span></p>
<p style="top:104.2pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibitor of IL-6/IL-</span></p>
<p style="top:113.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">6R/GP130 complex</span></p>
<p style="top:104.2pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">PDAC</span></p>
<p style="top:104.2pt;left:435.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">5</span></p>
<p style="top:104.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tumor marker reduction of 80%</span></p>
<p style="top:116.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Gastric adenocarcinoma</span></p>
<p style="top:116.7pt;left:435.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2</span></p>
<p style="top:116.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Stability of disease on CT in 60%</span></p>
<p style="top:129.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Regression on PET-CT in 60%</span></p>
<p style="top:141.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Beatty 2019</span></p>
<p style="top:141.7pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">52</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:141.7pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 1b/2 dose-</span></p>
<p style="top:151.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">finding study</span></p>
<p style="top:141.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Itacitinib</span></p>
<p style="top:141.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Selective</span></p>
<p style="top:151.2pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK1-inhibition</span></p>
<p style="top:141.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Advanced PDAC</span></p>
<p style="top:141.7pt;left:431.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">46</span></p>
<p style="top:141.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Terminated early due to futility of</span></p>
<p style="top:151.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JANUS study [</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">55</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:163.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ paclitaxel</span></p>
<p style="top:163.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Other advanced solid</span></p>
<p style="top:173.2pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">tumors</span></p>
<p style="top:163.7pt;left:435.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">9</span></p>
<p style="top:163.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Acceptable safety profile</span></p>
<p style="top:176.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ gemcitabine</span></p>
<p style="top:176.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Overall response rate: 24%</span></p>
<p style="top:188.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ng 2019</span></p>
<p style="top:188.7pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">53</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:188.7pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 1 dose-</span></p>
<p style="top:198.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">escalation study</span></p>
<p style="top:188.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Momelotinib</span></p>
<p style="top:188.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK1/2 inhibitor</span></p>
<p style="top:188.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Untreated metastatic PDAC</span></p>
<p style="top:188.7pt;left:431.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">25</span></p>
<p style="top:188.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">No significant increase in PFS or OS</span></p>
<p style="top:201.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ paclitaxel</span></p>
<p style="top:201.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">MTD: not reached</span></p>
<p style="top:213.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ gemcitabine</span></p>
<p style="top:213.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">AE: fatigue (80%), nausea (76%),</span></p>
<p style="top:223.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">anemia (68%).</span></p>
<p style="top:235.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Partial response in 28%, stable disease</span></p>
<p style="top:245.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">in 52%</span></p>
<p style="top:257.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Hurwitz</span></p>
<p style="top:267.2pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2015</span></p>
<p style="top:257.7pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">56</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:257.7pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:267.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 2</span></p>
<p style="top:257.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ruxolitinib</span></p>
<p style="top:257.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK1/2 inhibitor</span></p>
<p style="top:257.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Metastatic PDAC after</span></p>
<p style="top:267.2pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">treatment failure with</span></p>
<p style="top:276.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">gemcitabine</span></p>
<p style="top:257.7pt;left:428.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">127</span></p>
<p style="top:257.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">No significant increase in PFS</span></p>
<p style="top:270.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ capecitabine</span></p>
<p style="top:270.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Significant increase in OS in patients</span></p>
<p style="top:279.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">with inflammation compared to</span></p>
<p style="top:289.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">placebo (p = 0.011)</span></p>
<p style="top:301.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Grade 3 anemia more frequent</span></p>
<p style="top:311.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">compared to placebo</span></p>
<p style="top:323.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Bauer 2018</span></p>
<p style="top:323.7pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">54</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:323.7pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 1b dose-</span></p>
<p style="top:333.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">finding study</span></p>
<p style="top:323.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ruxolitinib</span></p>
<p style="top:323.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK1/2 inhibitor</span></p>
<p style="top:323.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Untreated advanced PDAC</span></p>
<p style="top:323.7pt;left:431.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">34</span></p>
<p style="top:323.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Terminated early due to disease</span></p>
<p style="top:333.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">progression in 81%</span></p>
<p style="top:345.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ gemcitabine</span></p>
<p style="top:345.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Other advanced solid</span></p>
<p style="top:355.2pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">tumors</span></p>
<p style="top:345.7pt;left:435.8pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">8</span></p>
<p style="top:345.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Overall response rate in PDAC: 23.5%</span></p>
<p style="top:358.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ paclitaxel</span></p>
<p style="top:358.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Acceptable toxicity profile</span></p>
<p style="top:370.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Hurwitz</span></p>
<p style="top:380.2pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2018</span></p>
<p style="top:370.7pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">55</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:370.7pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:380.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 3 (JANUS)</span></p>
<p style="top:370.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ruxolitinib</span></p>
<p style="top:370.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK1/2 inhibitor</span></p>
<p style="top:370.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Advanced PDAC</span></p>
<p style="top:370.7pt;left:428.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">307</span></p>
<p style="top:370.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Terminated early due to futility</span></p>
<p style="top:383.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ capecitabine</span></p>
<p style="top:383.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">No significant difference in PFS or OS</span></p>
<p style="top:395.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Acceptable toxicity profile</span></p>
<p style="top:408.2pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Eckhardt</span></p>
<p style="top:417.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2009</span></p>
<p style="top:408.2pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">57</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:408.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:417.7pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 3</span></p>
<p style="top:408.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tipifarnib</span></p>
<p style="top:417.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(R115777)</span></p>
<p style="top:408.2pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of STAT3</span></p>
<p style="top:417.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:408.2pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Advanced PDAC</span></p>
<p style="top:408.2pt;left:428.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">244</span></p>
<p style="top:408.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">No significant difference in survival</span></p>
<p style="top:430.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">+ gemcitabine</span></p>
<p style="top:430.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Acceptable toxicity profile</span></p>
<p style="top:442.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Most common AE: neutropenia,</span></p>
<p style="top:452.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">thrombocytopenia</span></p>
<p style="top:464.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Macdonald</span></p>
<p style="top:474.2pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">2005</span></p>
<p style="top:464.7pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">58</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:464.7pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:474.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 2</span></p>
<p style="top:464.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tipifarnib</span></p>
<p style="top:474.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(R115777)</span></p>
<p style="top:464.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of STAT3</span></p>
<p style="top:474.2pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:464.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Untreated advanced PDAC</span></p>
<p style="top:464.7pt;left:431.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">53</span></p>
<p style="top:464.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">6-month survival rate: 19%</span></p>
<p style="top:477.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Median time to treatment failure: 1.4</span></p>
<p style="top:486.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">months</span></p>
<p style="top:499.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">No single-agent antitumor activity</span></p>
<p style="top:511.7pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Cohen 2003</span></p>
<p style="top:511.7pt;left:85.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">[</span><span style="font-family:MinionPro,serif;font-size:8.0pt;color:#3c64ac">59</span><span style="font-family:MinionPro,serif;font-size:8.0pt">]</span></p>
<p style="top:511.7pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Randomized</span></p>
<p style="top:521.2pt;left:105.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 2</span></p>
<p style="top:511.7pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tipifarnib</span></p>
<p style="top:521.2pt;left:171.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(R115777)</span></p>
<p style="top:511.7pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of STAT3</span></p>
<p style="top:521.2pt;left:230.5pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:511.7pt;left:312.3pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Untreated advanced PDAC</span></p>
<p style="top:511.7pt;left:431.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">20</span></p>
<p style="top:511.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">100% progression at 6 months</span></p>
<p style="top:524.2pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">6-month survival rate: 25%</span></p>
<p style="top:536.7pt;left:446.1pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">No single-agent antitumor activity</span></p>
<p style="top:555.5pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">PFS: progression-free survival, OS: overall survival, MTD: maximum tolerable dose, AE: adverse event, PDAC: pancreatic ductal adenocarcinoma,&#x2014;indicates no data</span></p>
<p style="top:567.4pt;left:36.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">available</span></p>
<p style="top:585.5pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1371/journal.pone.0252397.t004</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:552.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">10 / 17</span></p>


<p style="top:76.9pt;left:200.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Table 5. Summary of findings by drug.</span></b></p>
<p style="top:91.7pt;left:200.0pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Drug</span></b></p>
<p style="top:91.7pt;left:291.4pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Mechanism of action</span></b></p>
<p style="top:91.7pt;left:379.6pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">Outcome</span></b></p>
<p style="top:91.7pt;left:476.8pt;line-height:8.0pt"><b><span style="font-family:MinionPro,serif;font-size:8.0pt">State of research</span></b></p>
<p style="top:104.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Bazedoxifene</span></p>
<p style="top:104.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibitor of IL-6/IL-6R/</span></p>
<p style="top:113.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">GP130 complex</span></p>
<p style="top:104.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:104.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Clinical study, retrospective</span></p>
<p style="top:116.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Synergism with paclitaxel</span></p>
<p style="top:126.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">and gemcitabine</span></p>
<p style="top:138.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ganetespib</span></p>
<p style="top:138.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">HSP90/JAK2</span></p>
<p style="top:138.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:138.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:151.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Synergism with</span></p>
<p style="top:160.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">gemcitabine/paclitaxel and</span></p>
<p style="top:170.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">5-fluorouracil/oxaliplatin</span></p>
<p style="top:182.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ruxolitinib</span></p>
<p style="top:182.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK1/2 inhibitor</span></p>
<p style="top:182.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Negative in combination</span></p>
<p style="top:192.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">with gemcitabine/paclitaxel</span></p>
<p style="top:182.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 1b clinical trial</span></p>
<p style="top:204.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Negative in combination</span></p>
<p style="top:214.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">with capecitabine</span></p>
<p style="top:204.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 2+3 clinical trial</span></p>
<p style="top:226.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tipifarnib (R1115777)</span></p>
<p style="top:226.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of STAT3</span></p>
<p style="top:236.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:226.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Negative as single agent</span></p>
<p style="top:226.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 2 clinical trials</span></p>
<p style="top:239.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Negative in combination</span></p>
<p style="top:248.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">with gemcitabine</span></p>
<p style="top:239.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 3 clinical trial</span></p>
<p style="top:261.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Momelotinib</span></p>
<p style="top:261.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK1/2 inhibitor</span></p>
<p style="top:261.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Negative</span></p>
<p style="top:261.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 1 clinical trial</span></p>
<p style="top:273.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Negative in combination</span></p>
<p style="top:283.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">with gemcitabine and</span></p>
<p style="top:292.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">paclitaxel</span></p>
<p style="top:305.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Itacitinib</span></p>
<p style="top:305.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Selective JAK-1</span></p>
<p style="top:314.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">inhibition</span></p>
<p style="top:305.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:305.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phase 2 clinical trial</span></p>
<p style="top:327.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">AG490</span></p>
<p style="top:327.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">JAK2 inhibitor</span></p>
<p style="top:327.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:327.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:339.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Cryptotanshinone</span></p>
<p style="top:339.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 inhibition</span></p>
<p style="top:339.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:339.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:352.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Cucurbitacin B</span></p>
<p style="top:352.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of</span></p>
<p style="top:361.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation of JAK2</span></p>
<p style="top:371.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">and STAT3</span></p>
<p style="top:352.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive; synergism with</span></p>
<p style="top:361.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">gemcitabine</span></p>
<p style="top:352.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:383.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Cucurbitacin E</span></p>
<p style="top:383.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of STAT3</span></p>
<p style="top:393.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:383.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:383.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:405.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ellagic acid</span></p>
<p style="top:405.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of STAT3</span></p>
<p style="top:415.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">phosphorylation</span></p>
<p style="top:405.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:405.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:427.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">FLLL31/32</span></p>
<p style="top:427.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Selective JAK2/STAT3</span></p>
<p style="top:437.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(SH2) inhibition</span></p>
<p style="top:427.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:427.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:449.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">IL-32</span><span style="font-family:SymbolGreekU,serif;font-size:8.0pt">&#x3b1;</span></p>
<p style="top:449.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of JAK2/</span></p>
<p style="top:459.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3</span></p>
<p style="top:449.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:449.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:471.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">IL-9 antibody</span></p>
<p style="top:471.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">IL-9 inhibition</span></p>
<p style="top:471.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:471.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:484.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">LLL12</span></p>
<p style="top:484.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Blocking of IL-6-induced</span></p>
<p style="top:493.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 phosphorylation</span></p>
<p style="top:484.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:484.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:506.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">LTP-1</span></p>
<p style="top:506.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 inhibitor</span></p>
<p style="top:506.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:506.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:518.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Morusin</span></p>
<p style="top:518.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 inhibitor</span></p>
<p style="top:518.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:518.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:531.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Phospho-valproic acid</span></p>
<p style="top:540.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(MDC-1112)</span></p>
<p style="top:531.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 inhibitor</span></p>
<p style="top:531.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive; synergism with</span></p>
<p style="top:540.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">gemcitabine</span></p>
<p style="top:531.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:553.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ponatinib</span></p>
<p style="top:553.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Multi-receptor tyrosine</span></p>
<p style="top:562.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">kinase inhibitor</span></p>
<p style="top:553.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:553.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:575.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">S-Adenosylmethionine</span></p>
<p style="top:584.7pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(SAM)</span></p>
<p style="top:575.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Inhibition of JAK2/</span></p>
<p style="top:584.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3</span></p>
<p style="top:575.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive; synergism with</span></p>
<p style="top:584.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">gemcitabine</span></p>
<p style="top:575.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:597.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">SZC015</span></p>
<p style="top:597.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Suppression of NF</span><span style="font-family:SymbolGreekU,serif;font-size:8.0pt">&#x3ba;</span><span style="font-family:MinionPro,serif;font-size:8.0pt">B</span></p>
<p style="top:606.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">and JAK2/STAT3</span></p>
<p style="top:597.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive</span></p>
<p style="top:597.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:619.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Tocilizumab</span></p>
<p style="top:619.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Anti-IL6R</span><span style="font-family:SymbolGreekU,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:MinionPro,serif;font-size:8.0pt">, humanized</span></p>
<p style="top:628.7pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">monoclonal antibody</span></p>
<p style="top:619.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Positive; synergism with</span></p>
<p style="top:628.7pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">gemcitabine</span></p>
<p style="top:619.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Preclinical research</span></p>
<p style="top:631.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ongoing clinical trials</span></p>
<p style="top:641.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">(NCT04258150,</span></p>
<p style="top:650.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">NCT02767557)</span></p>
<p style="top:663.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Napabucasin</span></p>
<p style="top:663.2pt;left:292.4pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">STAT3 inhibitor</span></p>
<p style="top:663.2pt;left:380.6pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ongoing</span></p>
<p style="top:663.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">Ongoing phase 1 and 3</span></p>
<p style="top:672.7pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">clinical trials (NCT02231723,</span></p>
<p style="top:682.2pt;left:477.9pt;line-height:8.0pt"><span style="font-family:MinionPro,serif;font-size:8.0pt">NCT02993731)</span></p>
<p style="top:697.2pt;left:200.0pt;line-height:8.0pt"><span style="font-family:Arial Narrow,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1371/journal.pone.0252397.t005</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:552.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">11 / 17</span></p>


<p style="top:76.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">The TME plays an important role in tumorigenesis and chemoresistance by close interac-</span></p>
<p style="top:89.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">tion with tumor cells. Furthermore, TME has been shown to be highly immunosuppressive,</span></p>
<p style="top:102.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">promoting immune evasion, hence sustaining tumor progression [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">18</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">20</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Immunotherapy, so</span></p>
<p style="top:115.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">far, has not demonstrated substantial clinical improvement as single agent in the treatment of</span></p>
<p style="top:128.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">PDAC [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">5</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Therefore, strategies simultaneously targeting PDAC tumor cells as well as different</span></p>
<p style="top:141.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">immune checkpoints might be needed. The interactions of PDAC tumor cells and different</span></p>
<p style="top:154.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">cells within the TME such as CAFs, MDSCs, TAMs, are mediated through GP130/JAK/STAT3</span></p>
<p style="top:167.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">pathway [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">11</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 17</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">20</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 68</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. STAT3 inhibition might thus have consequences in shaping TME</span></p>
<p style="top:180.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">towards anti-tumor phenotype by acting on both immune and tumor cells [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">18</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">20</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. In combi-</span></p>
<p style="top:193.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">nation with chemotherapeutic agents and immunotherapy, it might significantly increase ther-</span></p>
<p style="top:206.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">apeutic efficacy in the treatment of PDAC.</span></p>
<p style="top:219.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Recent studies have shown the important role of the STAT3 pathway in tumorigensis, as</span></p>
<p style="top:232.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">well as the STAT3-mediated resistance to chemotherapy in</span><i><span style="font-family:MinionPro,serif;font-size:10.0pt"> in vivo</span></i><span style="font-family:MinionPro,serif;font-size:10.0pt"> models of PDAC [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">8</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">15</span><span style="font-family:MinionPro,serif;font-size:10.0pt">].</span></p>
<p style="top:245.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">The results from the preclinical trials presented in this review confirmed the importance of the</span></p>
<p style="top:258.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">GP130/JAK/STAT3 pathway in PDAC and its role as a possible drug target. Furthermore, sev-</span></p>
<p style="top:271.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">eral of the studies showed a synergy between the investigational drug and chemotherapy, such</span></p>
<p style="top:284.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">as gemcitabine, paclitaxel, 5-fluorouracil, and oxaliplatin [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">31</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 33</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 38</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 40</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 41</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 45</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 49</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 53</span><span style="font-family:MinionPro,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">55</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 57</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span></p>
<p style="top:297.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">60</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. However, to the best of our knowledge, drugs targeting GP130/JAK/STAT3 have never</span></p>
<p style="top:310.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">been studied as chemosensitizers in addition to the currently emerging FOLFIRINOX regimen</span></p>
<p style="top:323.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">[</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">4</span><span style="font-family:MinionPro,serif;font-size:10.0pt">]. Even though some promising outcomes have been shown in clinical trials [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">51</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 52</span><span style="font-family:MinionPro,serif;font-size:10.0pt">], several</span></p>
<p style="top:336.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">studies were terminated prematurely due to high progression rates and futility. This may</span></p>
<p style="top:349.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">reflect the difficulty showing a significant benefit in patients presenting with PDAC, as it is</span></p>
<p style="top:362.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">known to be a highly lethal disease that is often diagnosed at an advanced stage and has a poor</span></p>
<p style="top:375.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">prognosis with an overall 5-year survival rate of 2&#x2013;9% [</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac">1</span><span style="font-family:MinionPro,serif;font-size:10.0pt">,</span><span style="font-family:MinionPro,serif;font-size:10.0pt;color:#3c64ac"> 2</span><span style="font-family:MinionPro,serif;font-size:10.0pt">].</span></p>
<p style="top:388.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">The discrepancy between preclinical and clinical data may also result from the fact that, in</span></p>
<p style="top:401.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">contrast to the preclinical studies, the clinical trials did not verify the activation of the STAT3</span></p>
<p style="top:414.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">pathway in PDAC. The benefit of targeted GP130/JAK/STAT3 therapy may be increased by</span></p>
<p style="top:427.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">selecting patients with previously known STAT3 pathway activation in PDAC cells.</span></p>
<p style="top:440.6pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">The present systematic review included all preclinical and clinical trials of drugs targeting</span></p>
<p style="top:453.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">the GP130/JAK/STAT3 pathway. Furthermore, we searched for ongoing, unpublished trials,</span></p>
<p style="top:466.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">leading to a thorough analysis of the current state of research. However, because all published</span></p>
<p style="top:479.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">preclinical studies reported a positive outcome, we suspect that several negative studies may</span></p>
<p style="top:492.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">not have been published and concluded relevant publication bias, leading to an overestimation</span></p>
<p style="top:505.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">of the effect of GP130/JAK/STAT3-targeting drugs in the treatment of PDAC in the preclinical</span></p>
<p style="top:518.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">setting. Furthermore, the substantial heterogeneity among the preclinical and clinical studies</span></p>
<p style="top:531.6pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">did not allow a quantitative analysis or measurement of the effect size.</span></p>
<p style="top:562.2pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Conclusion</span></b></p>
<p style="top:580.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Preclinical studies strongly suggest significant efficacy of drugs targeting GP130/JAK/STAT3 in</span></p>
<p style="top:593.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">the treatment of PDAC and that these molecules are effective chemosensitizers, possibly through</span></p>
<p style="top:606.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">simultaneous effect on tumor cells and TME. Though only a few trials have shown the efficacy</span></p>
<p style="top:619.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">in a clinical setting, the GP130/JAK/STAT3 pathway remains a promising drug target for the</span></p>
<p style="top:632.8pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">development of future treatments for PDAC and may help overcome chemotherapy resistance.</span></p>
<p style="top:663.4pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Supporting information</span></b></p>
<p style="top:682.0pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">S1 Checklist.</span></b></p>
<p style="top:695.0pt;left:200.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">(DOC)</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:552.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">12 / 17</span></p>


<p style="top:76.3pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">Author Contributions</span></b></p>
<p style="top:94.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Conceptualization:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin, Lucie Vignot, Carmen Gonelle-Gispert,</span></p>
<p style="top:107.9pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Leo Bu&#xa8;hler, Bernhard Egger.</span></p>
<p style="top:125.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Data curation:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin.</span></p>
<p style="top:143.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Formal analysis:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin.</span></p>
<p style="top:161.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Investigation:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl.</span></p>
<p style="top:179.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Methodology:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin.</span></p>
<p style="top:197.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Project administration:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin.</span></p>
<p style="top:215.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Supervision:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Leo Bu&#xa8;hler, Bernhard Egger.</span></p>
<p style="top:233.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Validation:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin, Lucie Vignot, Carmen Gonelle-Gispert, Leo Bu&#xa8;h-</span></p>
<p style="top:246.9pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">ler, Bernhard Egger.</span></p>
<p style="top:264.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Visualization:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin.</span></p>
<p style="top:282.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Writing &#x2013; original draft:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin.</span></p>
<p style="top:300.9pt;left:200.0pt;line-height:10.0pt"><b><span style="font-family:MinionPro,serif;font-size:10.0pt">Writing &#x2013; review &amp; editing:</span></b><span style="font-family:MinionPro,serif;font-size:10.0pt"> Sarah Peisl, Claudia Mellenthin, Lucie Vignot, Carmen Gonelle-</span></p>
<p style="top:313.9pt;left:212.0pt;line-height:10.0pt"><span style="font-family:MinionPro,serif;font-size:10.0pt">Gispert, Leo Bu&#xa8;hler, Bernhard Egger.</span></p>
<p style="top:356.4pt;left:200.0pt;line-height:12.0pt"><b><span style="font-family:Arial,serif;font-size:12.0pt">References</span></b></p>
<p style="top:373.1pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">1.</span></b></p>
<p style="top:373.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Yeo TP. Demographics, Epidemiology, and Inheritance of Pancreatic Ductal Adenocarcinoma. Semin</span></p>
<p style="top:382.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Oncol. 2015 Feb; 42(1):8&#x2013;18.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1053/j.seminoncol.2014.12.002</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 25726048</span></p>
<p style="top:395.6pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">2.</span></b></p>
<p style="top:395.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Baugh KA, Tran Cao HS, van Buren G, Silberfein EJ, Hsu C, Chai C, et al. Understaging of clinical</span></p>
<p style="top:405.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">stage I pancreatic cancer and the impact of multimodality therapy. Surgery. 2019 Feb; 165(2):307&#x2013;14.</span></p>
<p style="top:414.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1016/j.surg.2018.08.003</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 30243481</span></p>
<p style="top:427.6pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">3.</span></b></p>
<p style="top:427.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review</span></p>
<p style="top:437.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018 Nov 21; 24</span></p>
<p style="top:446.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(43):4846&#x2013;61.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.3748/wjg.v24.i43.4846</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 30487695</span></p>
<p style="top:459.6pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">4.</span></b></p>
<p style="top:459.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Singh RR, O&#x2019;Reilly EM. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.</span></p>
<p style="top:469.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Drugs. 2020 May 1; 80(7):647&#x2013;69.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1007/s40265-020-01304-0</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 32306207</span></p>
<p style="top:482.1pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">5.</span></b></p>
<p style="top:482.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Schizas D, Charalampakis N, Kole C, Economopoulou P, Koustas E, Gkotsis E, et al. Immunotherapy</span></p>
<p style="top:491.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">for pancreatic cancer: A 2020 update. Cancer Treat Rev. 2020 Jun; 86:102016.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1016/</span></p>
<p style="top:501.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">j.ctrv.2020.102016</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 32247999</span></p>
<p style="top:514.1pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">6.</span></b></p>
<p style="top:514.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lee JH, Mohan CD, Deivasigamani A, Jung YY, Rangappa S, Basappa S, et al. Brusatol suppresses</span></p>
<p style="top:523.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carci-</span></p>
<p style="top:533.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">noma. J Adv Res. 2020 Nov; 26:83&#x2013;94.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1016/j.jare.2020.07.004</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 33133685</span></p>
<p style="top:546.1pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">7.</span></b></p>
<p style="top:546.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Garg M, Shanmugam MK, Bhardwaj V, Goel A, Gupta R, Sharma A, et al. The pleiotropic role of tran-</span></p>
<p style="top:555.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">scription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention</span></p>
<p style="top:565.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">and therapy. Med Res Rev. 2020 Dec 1;</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1002/med.21761</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 33289118</span></p>
<p style="top:578.1pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">8.</span></b></p>
<p style="top:578.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, et al. STAT3 Plays a Critical</span></p>
<p style="top:587.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Role in KRAS-Induced Pancreatic Tumorigenesis. Cancer Res. 2011 Jul 15; 71(14):5020&#x2013;9.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.</span></p>
<p style="top:597.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">org/10.1158/0008-5472.CAN-11-0908</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 21586612</span></p>
<p style="top:610.1pt;left:204.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">9.</span></b></p>
<p style="top:610.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">O</span><sup><span style="font-family:Arial,serif;font-size:8.0pt">&#xa8; </span></sup><span style="font-family:Arial,serif;font-size:8.0pt">hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations</span></p>
<p style="top:619.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017; 214(3):579&#x2013;96.</span></p>
<p style="top:629.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1084/jem.20162024</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 28232471</span></p>
<p style="top:642.1pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">10.</span></b></p>
<p style="top:642.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Gruber R, Panayiotou R, Nye E, Spencer-Dene B, Stamp G, Behrens A. YAP1 and TAZ Control Pan-</span></p>
<p style="top:651.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">creatic Cancer Initiation in Mice by Direct Up-regulation of JAK&#x2013;STAT3 Signaling. Gastroenterology.</span></p>
<p style="top:661.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2016 Sep; 151(3):526&#x2013;39.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1053/j.gastro.2016.05.006</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 27215660</span></p>
<p style="top:674.1pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">11.</span></b></p>
<p style="top:674.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klo&#xa8;ppel G, et al. Stat3/Socs3 Activation by</span></p>
<p style="top:683.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of</span></p>
<p style="top:693.1pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Pancreatic Cancer. Cancer Cell. 2011 Apr; 19(4):456&#x2013;69.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1016/j.ccr.2011.03.009</span></p>
<p style="top:702.6pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 21481788</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:552.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">13 / 17</span></p>


<p style="top:76.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">12.</span></b></p>
<p style="top:76.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, et al. Hepatocytes direct the formation of</span></p>
<p style="top:86.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">a pro-metastatic niche in the liver. Nature. 2019 Mar; 567(7747):249&#x2013;52.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1038/</span></p>
<p style="top:95.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">s41586-019-1004-y</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 30842658</span></p>
<p style="top:108.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">13.</span></b></p>
<p style="top:108.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Tan F, Putoczki T, Stylli S, Luwor R. The Role of STAT3 Signaling in Mediating Tumor Resistance to</span></p>
<p style="top:118.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Cancer Therapy. Curr Drug Targets. 2014 Dec 16; 15(14):1341&#x2013;53.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.2174/</span></p>
<p style="top:127.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">1389450115666141120104146</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 25410411</span></p>
<p style="top:140.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">14.</span></b></p>
<p style="top:140.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, et al. Activation of the IL-6R/Jak/</span></p>
<p style="top:150.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma. J</span></p>
<p style="top:159.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Gastrointest Surg. 2013 May; 17(5):887&#x2013;98.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1007/s11605-013-2168-7</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span></p>
<p style="top:169.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">23435739</span></p>
<p style="top:182.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">15.</span></b></p>
<p style="top:182.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Xing H-B, Tong M-T, Wang J, Hu H, Zhai C-Y, Huang C-X, et al. Suppression of</span><i><span style="font-family:Arial,serif;font-size:8.0pt"> IL-6</span></i><span style="font-family:Arial,serif;font-size:8.0pt"> Gene by shRNA</span></p>
<p style="top:191.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells. BioMed Res Int.</span></p>
<p style="top:201.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2018; 2018:1&#x2013;10.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1155/2018/3195025</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 29693005</span></p>
<p style="top:214.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">16.</span></b></p>
<p style="top:214.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Xu S, Neamati N. Gp130: A promising drug target for cancer therapy. Expert Opin Ther Targets. 2013;</span></p>
<p style="top:223.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">17(11):1303&#x2013;28.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1517/14728222.2013.830105</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 24099136</span></p>
<p style="top:236.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">17.</span></b></p>
<p style="top:236.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Chen J, Wang S, Su J, Chu G, You H, Chen Z, et al. Interleukin-32</span><span style="font-family:Arial,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:Arial,serif;font-size:8.0pt"> inactivates JAK2/STAT3 signaling</span></p>
<p style="top:246.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pan-</span></p>
<p style="top:255.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">creatic cancer cells. OncoTargets Ther. 2016; 9:4225&#x2013;37.</span></p>
<p style="top:268.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">18.</span></b></p>
<p style="top:268.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancre-</span></p>
<p style="top:278.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">atic cancer. Clin Sci. 2020 Aug 28; 134(16):2091&#x2013;115.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1042/CS20191211</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span></p>
<p style="top:287.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">32808663</span></p>
<p style="top:300.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">19.</span></b></p>
<p style="top:300.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, et al. IL-6 as a major regulator of MDSC</span></p>
<p style="top:310.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">activity and possible target for cancer immunotherapy. Cell Immunol. 2021 Jan; 359:104254.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://</span></p>
<p style="top:319.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">doi.org/10.1016/j.cellimm.2020.104254</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 33296753</span></p>
<p style="top:332.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">20.</span></b></p>
<p style="top:332.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Trovato R, Fiore A, Sartori S, Can</span><span style="font-family:Arial,serif;font-size:8.0pt">&#xe8;</span><span style="font-family:Arial,serif;font-size:8.0pt"> S, Giugno R, Cascione L, et al. Immunosuppression by monocytic</span></p>
<p style="top:342.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by</span></p>
<p style="top:351.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">STAT3. J Immunother Cancer. 2019 Dec; 7(1):255.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1186/s40425-019-0734-6</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span></p>
<p style="top:361.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">31533831</span></p>
<p style="top:374.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">21.</span></b></p>
<p style="top:374.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: A highly regulated and dynamic sys-</span></p>
<p style="top:383.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">tem. Cytokine. 2014 Nov; 70(1):11&#x2013;20.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1016/j.cyto.2014.05.024</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 24986424</span></p>
<p style="top:396.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">22.</span></b></p>
<p style="top:396.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Jin G, Hong W, Guo Y, Bai Y, Chen B. Molecular Mechanism of Pancreatic Stellate Cells Activation in</span></p>
<p style="top:406.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Chronic Pancreatitis and Pancreatic Cancer. J Cancer. 2020; 11(6):1505&#x2013;15.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.7150/</span></p>
<p style="top:415.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">jca.38616</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 32047557</span></p>
<p style="top:428.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">23.</span></b></p>
<p style="top:428.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, et al. The IL-6/JAK/Stat3 feed-forward</span></p>
<p style="top:438.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">loop drives tumorigenesis and metastasis. Neoplasia U S. 2013; 15(7):848&#x2013;62.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1593/</span></p>
<p style="top:447.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">neo.13706</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 23814496</span></p>
<p style="top:460.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">24.</span></b></p>
<p style="top:460.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-</span></p>
<p style="top:470.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">analyses: The PRISMA statement. Int J Surg. 2010; 8(5):336&#x2013;41.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1016/j.ijsu.2010.02.</span></p>
<p style="top:479.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">007</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 20171303</span></p>
<p style="top:492.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">25.</span></b></p>
<p style="top:492.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Higgins JPT, Altman DG, G</span><span style="font-family:Arial,serif;font-size:8.0pt">&#xf8;</span><span style="font-family:Arial,serif;font-size:8.0pt">tzsche PC, Ju&#xa8;ni P, Moher D, Oxman AD, et al. The Cochrane Collabora-</span></p>
<p style="top:502.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">tion&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18; 343:d5928&#x2013;d5928.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://</span></p>
<p style="top:511.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">doi.org/10.1136/bmj.d5928</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 22008217</span></p>
<p style="top:524.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">26.</span></b></p>
<p style="top:524.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYR-</span></p>
<p style="top:534.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">CLE&#x2019;s risk of bias tool for animal studies. BMC Med Res Methodol. 2014 Mar 26; 14(1):43.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.</span></p>
<p style="top:543.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">org/10.1186/1471-2288-14-43</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 24667063</span></p>
<p style="top:556.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">27.</span></b></p>
<p style="top:556.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Chen X, Tian J, Su GH, Lin J. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/ Proliferation, Glycol-</span></p>
<p style="top:566.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">ysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. Curr Cancer Drug Targets. 2019;</span></p>
<p style="top:575.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">19(5):417&#x2013;27.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.2174/1568009618666180430123939</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 29714141</span></p>
<p style="top:588.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">28.</span></b></p>
<p style="top:588.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Edderkaoui M, Lugea A, Hui H, Eibl G, Lu QY, Moro A, et al. Ellagic acid and embelin affect key cellular</span></p>
<p style="top:598.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">components of pancreatic adenocarcinoma, cancer, and stellate cells. Nutr Cancer. 2013; 65(8):1232&#x2013;</span></p>
<p style="top:607.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">44.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1080/01635581.2013.832779</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 24127740</span></p>
<p style="top:620.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">29.</span></b></p>
<p style="top:620.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Fu S, Lin J. Blocking interleukin-6 and interleukin-8 signaling inhibits cell viability, colony-forming activ-</span></p>
<p style="top:630.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">ity, and cell migration in human triple-negative breast cancer and pancreatic cancer cells. Anticancer</span></p>
<p style="top:639.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Res. 2018; 38(11):6271&#x2013;9.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.21873/anticanres.12983</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 30396947</span></p>
<p style="top:652.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">30.</span></b></p>
<p style="top:652.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Ge Y, Yang B, Chen Z, Cheng R. Cryptotanshinone suppresses the proliferation and induces the apo-</span></p>
<p style="top:662.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">ptosis of pancreatic cancer cells via the STAT3 signaling pathway. Mol Med Rep. 2015; 12(5):7782&#x2013;8.</span></p>
<p style="top:671.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.3892/mmr.2015.4379</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 26459366</span></p>
<p style="top:684.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">31.</span></b></p>
<p style="top:684.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Goumas FA, Holmer R, Egberts JH, Gontarewicz A, Heneweer C, Geisen U, et al. Inhibition of IL-6 sig-</span></p>
<p style="top:694.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">naling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:552.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">14 / 17</span></p>


<p style="top:76.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">pancreatic cancer. Int J Cancer. 2015; 137(5):1035&#x2013;46.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1002/ijc.29445</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span></p>
<p style="top:86.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">25604508</span></p>
<p style="top:99.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">32.</span></b></p>
<p style="top:99.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, et al. Novel STAT3 phosphorylation inhibitors</span></p>
<p style="top:108.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010; 70</span></p>
<p style="top:118.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(6):2445&#x2013;54.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1158/0008-5472.CAN-09-2468</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 20215512</span></p>
<p style="top:131.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">33.</span></b></p>
<p style="top:131.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Long KB, Tooker G, Tooker E, Luque SL, Lee JW, Pan X, et al. IL6 receptor blockade enhances chemo-</span></p>
<p style="top:140.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">therapy efficacy in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2017; 16(9):1898&#x2013;908.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://</span></p>
<p style="top:150.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">doi.org/10.1158/1535-7163.MCT-16-0899</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 28611107</span></p>
<p style="top:163.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">34.</span></b></p>
<p style="top:163.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Palagani V, Bozko P, El khatib M, Belahmer H, Giese N, Sipos B, et al. Combined inhibition of Notch</span></p>
<p style="top:172.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. Carcinogene-</span></p>
<p style="top:182.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">sis. 2014; 35(4):859&#x2013;66.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1093/carcin/bgt394</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 24293409</span></p>
<p style="top:195.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">35.</span></b></p>
<p style="top:195.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Sahu N, Chan E, Chu F, Pham T, Koeppen H, Forrest W, et al. Cotargeting of MEK and PDGFR/STAT3</span></p>
<p style="top:204.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">pathways to treat pancreatic ductal adenocarcinoma. Vol. 16, Molecular Cancer Therapeutics. 2017.</span></p>
<p style="top:214.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">1729 p.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1158/1535-7163.MCT-17-0009</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 28619758</span></p>
<p style="top:227.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">36.</span></b></p>
<p style="top:227.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Sun C, Zhang M, Shan X, Zhou X, Yang J, Wang Y, et al. Inhibitory effect of cucurbitacin E on pancre-</span></p>
<p style="top:236.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">atic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol. 2010 Apr; 136(4):603&#x2013;10.</span></p>
<p style="top:246.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1007/s00432-009-0698-x</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 19816711</span></p>
<p style="top:259.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">37.</span></b></p>
<p style="top:259.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, et al. Cucurbitacin B induces</span></p>
<p style="top:268.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine</span></p>
<p style="top:278.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">on pancreatic cancer cells. Cancer Res. 2009; 69(14):5876&#x2013;84.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1158/0008-5472.</span></p>
<p style="top:287.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">CAN-09-0536</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 19605406</span></p>
<p style="top:300.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">38.</span></b></p>
<p style="top:300.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Wu X, Cao Y, Xiao H, Li C, Lin J. Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer ther-</span></p>
<p style="top:310.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">apy. Mol Cancer Ther. 2016; 15(11):2609&#x2013;19.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1158/1535-7163.MCT-15-0921</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span></p>
<p style="top:319.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">27535971</span></p>
<p style="top:332.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">39.</span></b></p>
<p style="top:332.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Zhang X, Lu H, Hong W, Liu L, Wang S, Zhou M, et al. Tyrphostin B42 attenuates trichostatin A-medi-</span></p>
<p style="top:342.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">ated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling. Oncol Rep.</span></p>
<p style="top:351.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2018; 39(4):1892&#x2013;900.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.3892/or.2018.6241</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 29393444</span></p>
<p style="top:364.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">40.</span></b></p>
<p style="top:364.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Nagaraju GP, Mezina A, Shaib WL, Landry J, El-Rayes BF. Targeting the Janus-activated kinase-2-</span></p>
<p style="top:374.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Eur J Cancer.</span></p>
<p style="top:383.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2016; 52:109&#x2013;19.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1016/j.ejca.2015.10.057</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 26682870</span></p>
<p style="top:396.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">41.</span></b></p>
<p style="top:396.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Nagaraju GP, Zakka KM, Landry JC, Shaib WL, Lesinski GB, El-Rayes BF. Inhibition of HSP90 over-</span></p>
<p style="top:406.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">comes resistance to chemotherapy and radiotherapy in pancreatic cancer. Int J Cancer. 2019 Sep 15;</span></p>
<p style="top:415.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">145(6):1529&#x2013;37.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1002/ijc.32227</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 30801702</span></p>
<p style="top:428.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">42.</span></b></p>
<p style="top:428.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lu D, Qin Q, Lei R, Hu B, Qin S. Targeted blockade of interleukin 9 inhibits tumor growth in murine</span></p>
<p style="top:438.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">model of pancreatic cancer. Adv Clin Exp Med. 2019; 28(10):1285&#x2013;92.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.17219/acem/</span></p>
<p style="top:447.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">104543</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 31647203</span></p>
<p style="top:460.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">43.</span></b></p>
<p style="top:460.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Liu A, Yan L, Pui-Kai L, Chenglong L, Lin J. LLL12 Inhibits Endogenous and Exogenous Interleukin-6-</span></p>
<p style="top:470.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">induced STAT3 Phosphorylation in Human Pancreatic Cancer Cells Aiguo. Anticancer Res. 2011;(1).</span></p>
<p style="top:483.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">44.</span></b></p>
<p style="top:483.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Huang HL, Chao MW, Chen CC, Cheng CC, Chen MC, Lin CF, et al. LTP-1, a novel antimitotic agent</span></p>
<p style="top:492.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">and Stat3 inhibitor, inhibits human pancreatic carcinomas in vitro and in vivo. Sci Rep. 2016; 6(Janu-</span></p>
<p style="top:502.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">ary):1&#x2013;11.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1038/srep27794</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 27278358</span></p>
<p style="top:515.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">45.</span></b></p>
<p style="top:515.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Luo D, D M.G., Wei R, LComb JL, Williams BR, Macken. Phospho-valproic acid (MDC-1112) reduces</span></p>
<p style="top:524.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when</span></p>
<p style="top:534.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">combined with gemcitabine. 2019; 40:1&#x2013;30.</span></p>
<p style="top:547.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">46.</span></b></p>
<p style="top:547.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Kim C, Kim JH, Oh EY, Nam D, Lee SG, Lee J, et al. Blockage of STAT3 signaling pathway by morusin</span></p>
<p style="top:556.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">induces apoptosis and inhibits invasion in human pancreatic tumor cells. Pancreas. 2016; 45(3):409&#x2013;</span></p>
<p style="top:566.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">19.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1097/MPA.0000000000000496</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 26646273</span></p>
<p style="top:579.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">47.</span></b></p>
<p style="top:579.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Venkatasubbarao K, Choudary A, Freeman JW. Farnesyl transferase inhibitor (R115777)-induced inhi-</span></p>
<p style="top:588.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">bition of STAT3 (Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular sig-</span></p>
<p style="top:598.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">nal-regulated kinases. Cancer Res. 2005; 65(7):2861&#x2013;71.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1158/0008-5472.CAN-04-</span></p>
<p style="top:607.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">2396</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 15805288</span></p>
<p style="top:620.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">48.</span></b></p>
<p style="top:620.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cyto-</span></p>
<p style="top:630.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">toxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.</span></p>
<p style="top:639.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">OncoImmunology. 2017; 6(3):1&#x2013;15.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1080/2162402X.2017.1291106</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 28405527</span></p>
<p style="top:652.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">49.</span></b></p>
<p style="top:652.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Liu Y, Bi T, Liu L, Gao Q, Shen G, Qin L. S-Adenosylmethionine synergistically enhances the antitumor</span></p>
<p style="top:662.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Naunyn Schmiede-</span></p>
<p style="top:671.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">bergs Arch Pharmacol. 2019; 392(5):615&#x2013;22.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1007/s00210-019-01617-2</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span></p>
<p style="top:681.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">30683944</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:552.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">15 / 17</span></p>


<p style="top:76.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">50.</span></b></p>
<p style="top:76.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Song Y, Gao L, Tang Z, Li H, Sun B, Chu P, et al. Anticancer effect of SZC015 on pancreatic cancer via</span></p>
<p style="top:86.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">mitochondria-dependent apoptosis and the constitutive suppression of activated nuclear factor</span><span style="font-family:Arial,serif;font-size:8.0pt"> &#x3ba;</span><span style="font-family:Arial,serif;font-size:8.0pt">B and</span></p>
<p style="top:95.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">STAT3 in vitro and in vivo. J Cell Physiol. 2018; 234(1):777&#x2013;88.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1002/jcp.26892</span></p>
<p style="top:105.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 30078206</span></p>
<p style="top:118.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">51.</span></b></p>
<p style="top:118.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Burkhardt C, Bu&#xa8;hler L, Tihy M, Morel P, Forni M. Bazedoxifene as a novel strategy for treatment of pan-</span></p>
<p style="top:127.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">creatic and gastric adenocarcinoma. Oncotarget. 2019; 10(34):3198&#x2013;202. PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 31139333</span></p>
<p style="top:140.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">52.</span></b></p>
<p style="top:140.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, Donehower R, et al. A Phase Ib/II Study of the JAK1</span></p>
<p style="top:150.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Inhibitor, Itacitinib, plus nab -Paclitaxel and Gemcitabine in Advanced Solid Tumors. The Oncologist.</span></p>
<p style="top:159.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2019; 24(1):14&#x2013;14.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1634/theoncologist.2017-0665</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 30115734</span></p>
<p style="top:172.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">53.</span></b></p>
<p style="top:172.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, et al. Phase 1 dose-escalation study of mome-</span></p>
<p style="top:182.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">lotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previ-</span></p>
<p style="top:191.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">ously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019; 37(1):159&#x2013;65.</span></p>
<p style="top:201.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1007/s10637-018-0650-5</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 30105668</span></p>
<p style="top:214.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">54.</span></b></p>
<p style="top:214.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Bauer TM, Rpatel M, Forero-Torres A, George TJ, Assad A, Du Y, et al. Aphase Ib study of ruxolitinib +</span></p>
<p style="top:223.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">gemcitabine</span><span style="font-family:Arial,serif;font-size:8.0pt"> &#xb1;</span><span style="font-family:Arial,serif;font-size:8.0pt"> nab-paclitaxel in patients with advanced solid tumors. OncoTargets Ther. 2018;</span></p>
<p style="top:233.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">11:2399&#x2013;407.</span></p>
<p style="top:246.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">55.</span></b></p>
<p style="top:246.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, et al. Ruxolitinib + capecitabine in</span></p>
<p style="top:255.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy:</span></p>
<p style="top:265.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018; 36(4):683&#x2013;95.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/</span></p>
<p style="top:274.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">10.1007/s10637-018-0580-2</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 29508247</span></p>
<p style="top:287.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">56.</span></b></p>
<p style="top:287.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, et al. Randomized, double-blind,</span></p>
<p style="top:297.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pan-</span></p>
<p style="top:306.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">creatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015; 33(34):4039&#x2013;47.</span></p>
<p style="top:316.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">https://doi.org/10.1200/JCO.2015.61.4578</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 26351344</span></p>
<p style="top:329.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">57.</span></b></p>
<p style="top:329.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Eckhardt SG, De Porre P, Smith D, Maurel J, Steward WP, Bouche O, et al. Patient-Reported Out-</span></p>
<p style="top:338.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">comes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in</span></p>
<p style="top:348.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Advanced Pancreatic Cancer. J Pain Symptom Manage. 2009; 37(2):135&#x2013;43.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1016/j.</span></p>
<p style="top:357.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">jpainsymman.2008.02.007</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 18723314</span></p>
<p style="top:370.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">58.</span></b></p>
<p style="top:370.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL, Giguere JK, et al. A phase II study of farne-</span></p>
<p style="top:380.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">syl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924)</span></p>
<p style="top:389.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">study. Invest New Drugs. 2005 Oct 1; 23(5):485&#x2013;7.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1007/s10637-005-2908-y</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span></p>
<p style="top:399.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">16133800</span></p>
<p style="top:412.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">59.</span></b></p>
<p style="top:412.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, et al. Phase II and Pharmaco-</span></p>
<p style="top:421.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">dynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Meta-</span></p>
<p style="top:431.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">static Pancreatic Adenocarcinoma. J Clin Oncol. 2003 Apr 1; 21(7):1301&#x2013;6.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1200/</span></p>
<p style="top:440.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">JCO.2003.08.040</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 12663718</span></p>
<p style="top:453.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">60.</span></b></p>
<p style="top:453.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, et al. Cucurbitacin B Induces</span></p>
<p style="top:463.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcita-</span></p>
<p style="top:472.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">bine on Pancreatic Cancer Cells. Cancer Res. 2009 Jul 15; 69(14):5876&#x2013;84.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1158/</span></p>
<p style="top:482.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">0008-5472.CAN-09-0536</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 19605406</span></p>
<p style="top:495.4pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">61.</span></b></p>
<p style="top:495.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cyto-</span></p>
<p style="top:504.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">toxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.</span></p>
<p style="top:514.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Oncoimmunology. 2017; 6(3):e1291106.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1080/2162402X.2017.1291106</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span></p>
<p style="top:523.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">28405527</span></p>
<p style="top:536.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">62.</span></b></p>
<p style="top:536.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Sun C, Zhang M, Shan X, Zhou X, Yang J, Wang Y, et al. Inhibitory effect of cucurbitacin e on pancreatic</span></p>
<p style="top:546.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol. 2010; 136(4):603&#x2013;10.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.</span></p>
<p style="top:555.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">org/10.1007/s00432-009-0698-x</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 19816711</span></p>
<p style="top:568.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">63.</span></b></p>
<p style="top:568.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al. Napabucasin versus placebo in refractory</span></p>
<p style="top:578.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">advanced colorectal cancer: a randomised phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Apr 1; 3</span></p>
<p style="top:587.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(4):263&#x2013;70.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1016/S2468-1253(18)30009-8</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 29397354</span></p>
<p style="top:600.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">64.</span></b></p>
<p style="top:600.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Yavropoulou MP, Makras P, Anastasilakis AD. Bazedoxifene for the treatment of osteoporosis. Expert</span></p>
<p style="top:610.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Opin Pharmacother. 2019 Jul 3; 20(10):1201&#x2013;10.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1080/14656566.2019.1615882</span></p>
<p style="top:619.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 31091133</span></p>
<p style="top:632.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">65.</span></b></p>
<p style="top:632.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">You H, Xu D, Zhao J, Li J, Wang Q, Tian X, et al. JAK Inhibitors: Prospects in Connective Tissue Dis-</span></p>
<p style="top:642.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">eases. Clin Rev Allergy Immunol. 2020 Dec; 59(3):334&#x2013;51.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1007/s12016-020-08786-</span></p>
<p style="top:651.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">6</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 32222877</span></p>
<p style="top:664.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">66.</span></b></p>
<p style="top:664.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Srinivas N, Barbour AM, Epstein N, Zhou G, Petusky S, Xun Z, et al. The Effect of Renal Impairment on</span></p>
<p style="top:674.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">the Pharmacokinetics and Safety of Itacitinib. J Clin Pharmacol. 2020 Aug; 60(8):1022&#x2013;9.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.</span></p>
<p style="top:683.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">org/10.1002/jcph.1601</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 32149388</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:552.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">16 / 17</span></p>


<p style="top:76.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">67.</span></b></p>
<p style="top:76.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, et al. JAK-Inhibitors for the Treat-</span></p>
<p style="top:86.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">ment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules.</span></p>
<p style="top:95.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2020 Jul 5; 10(7):1002.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.3390/biom10071002</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 32635659</span></p>
<p style="top:108.9pt;left:200.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">68.</span></b></p>
<p style="top:108.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibro-</span></p>
<p style="top:118.4pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">blasts in pancreatic cancer. J Hematol OncolJ Hematol Oncol. 2017 Dec; 10(1):76.</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.</span></p>
<p style="top:127.9pt;left:221.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac">1186/s13045-017-0448-5</span><span style="font-family:Arial,serif;font-size:8.0pt"> PMID:</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> 28351381</span></p>
<p style="top:37.4pt;left:35.0pt;line-height:11.0pt"><span style="font-family:Gotham,serif;font-size:11.0pt;color:#020304">PLOS ONE</span></p>
<p style="top:39.8pt;left:445.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Targeting STAT3 in pancreatic cancer</span></p>
<p style="top:749.6pt;left:36.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">PLOS ONE |</span><span style="font-family:Arial,serif;font-size:8.0pt;color:#3c64ac"> https://doi.org/10.1371/journal.pone.0252397</span></p>
<p style="top:749.6pt;left:245.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">June 17, 2021</span></p>
<p style="top:749.6pt;left:552.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">17 / 17</span></p>

</div>
